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Abstract: Mesoporous silica materials (MSM) have a great surface area and a high pore volume, 
meaning that they consequently have a large loading capacity, and have been demonstrated to be 
unique candidates for the treatment of different pathologies, including bacterial infection. In this 
text, we review the multiple ways of action in which MSM can be used to fight bacterial infection, 
including early detection, drug release, targeting bacteria or biofilm, antifouling surfaces, and 
adjuvant capacity (Scheme 1). This review focus mainly on those that act as a drug delivery system, 
and therefore that have an essential characteristic, which is their great loading capacity. Since MSM 
have advantages in all stages of combatting bacterial infection; its prevention, detection and finally 
in its treatment, we can venture to talk about them as the “nightmare of bacteria”. 
 
Scheme 1. Scheme summarizing the multiple ways of action in which MSM can be used to fight 
bacterial infection. 
Keywords: mesoporous silica; drug delivery; bacterial infection; bacterial biofilm; biofilm; 
antibiotic resistance; targeting bacteria; targeting biofilm, multifunctional nanoparticles 
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1. Introduction 
Despite living in a society increasingly concerned about hygiene and asepsis, in reality, we live 
in a world populated by microorganisms that can be found in the most unsuspected places, such as 
the door handle, the mobile phone, or on the kitchen sponge [1–4]. Although some of them do not 
cause any serious harm or can even be beneficial [5,6], others can be highly damaging, 
compromising our health, and even causing death. Since the mid-20th century, society has become 
aware of this, and has begun developing numerous antibiotics that can efficiently fight bacteria and 
greatly reduce mortality from infections. However, in recent years, this trend has begun to change, 
mainly due to an unjustified and continued use of antibiotics that is forcing bacteria to develop 
resistance against common antibacterial drugs [7,8]. In 2016, the European Food Safety Authority 
(EFSA) and the European Centre for Disease Prevention and Control (ECDC) conducted a study in 
28 European member states. This study demonstrates an increased resistance to certain antibiotics in 
Salmonella, Campylobacter, Escherichia coli, and Staphylococcus aureus bacteria [9].  
In addition to this acquired resistance, bacteria have an innate self-defense mechanism called 
biofilm formation [10]. Biofilms are defined as communities of microorganisms that grow adhered to 
a surface, and that are embedded in a protective self-produced extracellular matrix. This gives them 
certain and special characteristics, making them different from bacteria in a planktonic state (that is, 
as individual cells floating in solution), and able to play the important role of providing an increased 
resistance to antibiotics [11].  
Combined together, these two phenomena; having an acquired resistance to antibiotics and 
making biofilm formations, reduce bacterial sensitivity to antibiotics and hinder the effectiveness of 
medication. As a consequence, in order for the antibiotic to be effective, it is necessary to increase the 
dose and frequency of the treatments, favoring again the appearance of resistant bacteria; a vicious 
circle that seems to have no end. This is not to mention the side effects, such as hypersensitivity, the 
effects of commensal flora, or the appearance of opportunistic pathogens in the human body that can 
be caused by an abusive and prolonged consumption of antibiotics.[12] As a result, it has become 
necessary to explore new and more effective paths to the early detection and treatment of bacterial 
infections. Numerous efforts are being made to find alternatives such as the use of predatory 
bacteria [13], bacteriophages [14], bacteriocins [15], probiotics and prebiotics [16,17], etc. However, 
until now, none of them has shown efficacy that is comparable to that of antibiotics. 
Of course, another solution is the design of new antibiotics to which the bacteria are not yet 
resistant. In fact, according to a recent report by PEW, currently there are 45 new antibiotics in 
different phases of the clinical study[18]. The problem is that without a change of behavior regarding 
the use of antibiotics, after a short time, these drugs will stop being effective, and the vicious circle 
would return to its beginning. Therefore, the solution is not to design new drugs continuously, but 
to increase the durability and effectiveness of those that are known. This can be accomplished by the 
use of nanomaterials (NMs), which in recent years, have proven to be a great alternative in the 
treatment of infection and other diseases [19,20]. 
 Nanomaterials, with at least one of their dimensions in the order of nanometers, have a 
characteristic size that is halfway between the molecules and bulk materials, which allows them to 
interact uniquely with bacteria. In many cases, when NMs are in contact with the bacteria, they can 
disrupt the bacterial cell wall with no need for internalization, resulting in its toxicity, due to a 
simple matter of size. However, the way in which each type of NMs destroys or affects bacteria is 
extremely dependent on the NM’s composition, as well as the strain of the bacteria to be treated. In 
general, for metal NMs such as gold, or silver, their toxicities lie mainly in their ability to release 
metal ions into the environment, generate reactive oxygen species (ROS), or produce some 
photothermal effects [21]. Similarly, the use of some TiO2 or ZnO quantum dots for antibacterial 
treatment are due to their ability to produce ROS, especially after UV light irradiation [22]. Cationic 
peptides are also used with antimicrobial purposes taking advantage of its hydrophobicity, and 
especially its cationic nature that is able to physically damage the bacterial membrane through 
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electrostatic interactions [23]. Recently, more and more importance is being given to the use of 
different drug delivery nanomaterials, and although they may not have a clear antibiotic effect by 
themselves, they do allow for the loading and release of antibiotics when needed, enhancing their 
therapeutic capacity [24,25]. Liposomes [26,27], polymeric nanoparticles [28], and mesoporous silica 
materials (MSM) are some of the most common nanocarriers that used for this purpose. Despite their 
great biocompatibility, liposomes present poor stability and low loading capacity. On the other 
hand, polymeric nanoparticles usually present a fast release of the cargo, due to the degradation of 
the polymer shell, hindering their application for prolonged treatments [29]. Both issues can be 
overcome by the use of MSM, which are robust materials that remain stable for long periods, and 
that have a great surface area and high pore volume, meaning that they have a large loading 
capacity.[30] In addition, MSM allow for the achievement of high tunability at different levels; see 
below. 
1.1. Tunability of the Porous Structure 
By varying the synthesis conditions and the nature of the reagents, it is possible to modify the 
structure, composition, and size of the pores, adapting them to the requirements [31,32]. This is of 
great importance when designing a controlled release system. Thus, depending on the drug to be 
loaded, it may be necessary to increase or decrease the size of the pore to avoid steric impediments. 
By modifying the nature of the functional groups of the silica network, it is possible to control the 
drug/matrix interactions. In addition, the type of porous structure affects the process of 
adsorption/desorption of the drug. The most common porous silica structures for drug delivery are 
shown in Figure 1, with MCM-41 being the most frequent for the treatment of bacterial infection, 
according to the literature.  
 
Figure 1. The most common porous silica structures for drug delivery: (A) hexagonal MCM-41; (B) 
cubic MCM-48 (adapted with permission from [33], copyright PUBLISHER YEAR); (C) hexagonal 
with microporous connections SBA-15 (adapted with permission from [34], copyright PUBLISHER 
YEAR); (D) disorder LMU-1 (adapted with permission from [35], copyright PUBLISHER YEAR); (E) 
mesocellular foam IBN-3 [36,37], copyright PUBLISHER YEAR; (F) dendritic pores [38], copyright 
PUBLISHER YEAR; (G) mesoporous hollow particles [39], copyright PUBLISHER YEAR. 
All of these factors having a great influence on the loading capacity and the release kinetics of 
the drug. Thanks to this versatility, looking for the right combination of the different parameters 
(size, interaction type, and porous structure) it is possible to use MSM to load and release any 
antibiotic, drug, or other type of molecules. 
1.2. Tunability of the Shape of the Nanodevice 
MSM can be modified from a bulk material into a well-controlled size of nano- or micrometer 
particles. Their shape can also be changed into the form of rods [40], oblates [41], or their most 
A) B) C) D)
E) F) G)
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common, spherical shapes, amongst many other forms. Several studies have been performed on how 
the shape and the size of MSM affects its interaction with cells [42,43]. However, there are only a few 
studies on how these parameters affect bacteria. Rezwan et al. studied the effect on the viability of B. 
subtilis, B. megaterium, and E. coli when exposing them to three different sizes of silica particles (15, 50 
and 500 nm), observing no significant reduction of colony forming units (CFU) compared to the 
control [44]. Recently, T. Cohen-Bouhacina et al. suggested that only counting CFU might be 
insufficient to probe any toxicity as it could be affected by splitting effects [45]. After carrying out 
atomic force microscopy (AFM) experiments on E. coli bacteria with silica nanoparticles between 4 
and 100 nm, they observed a critical particle diameter in the range 50-80 nm. Thus, while particles 
below this size produced partial collapse or lysis of the cell membrane, the larger particles did not 
show any effect on the bacterial morphology. Regarding how the size and shape of silica particles 
affect biofilms, M. H. Schoenfisch reported that for nitric oxide-releasing silica particles and rods, 
smaller sizes and higher aspect ratios were more effective in biofilm eradication [46]. Although a 
deeper study is needed, it seems that both particle size and shape affect bacteria and biofilms, and 
are therefore important factors to consider when designing a nanocarrier.  
1.3. Tunability of the Nature of the Surface 
Silica materials have a high number of silanol groups on their surface, which allows us to easily 
modify the physicochemical nature of the surface through the process of functionalization [47,48], 
endowing them with great versatility, since it is possible: i) to include dyes in the structure to detect 
and follow the evolution of the infection [49–52]; ii) to incorporate positive functional groups that 
produce disruption of the bacteria’s outer membrane [45]; iii) to produce stimuli-responsive devices 
[53,54], iv) to bind molecules in order to obtain antiadherent surfaces that reduce bacterial adhesion, 
and that therefore create biofilm formation [55]; v) to tune the surface with targeting molecules that 
enhance bacteria or biofilm penetration [56]. 
In addition to all these properties, it has been demonstrated that MSM act as adjuvants, 
activating the immune response, and therefore, contributing to increasing the effectiveness of the 
vaccine and its immunological power [57,58]. 
Despite all the advantages that MSM present as drug delivery systems (DDS) for the treatment 
of different pathologies [53,59,60], there is no perfect material  that can be used alone for MSM. 
Increasingly, the scientific community devotes more time to combining different materials whose 
properties can be combined to achieve more polyvalent devices. In this sense, the combination of 
mesoporous silica materials with other elements, such as gold or silver nanoparticles, quantum dots, 
and different polymers or molecules, can produce an antimicrobial synergistic effect. Figure 2 shows 
the most common models of MSM in the form of nanoparticles (MSNPs) for drug delivery [61]. It is 
important to highlight that the same models can be presented with other shapes, but the sphere has 
been chosen for the example, as it is the most commonly used.  
 
Figure 2. The most common types of mesoporous silica materials (MSM) in the form of nanoparticles 
(MSNPs) that are used as drug delivery systems: (A) bare MSNPs; (B) (metal or other material NP 
core) @ (mesoporous silica shell); (C) metal NPs/MSNPs; (D) MSNPs coated with a polymer shell and 
(E) molecule functionalized-MSNPs. 
Since MSM have advantages in all stages of combatting bacterial infection, starting with its 
prevention, through its detection and finally in its treatment, we could venture to talk about them as 
the “nightmare of bacteria”. However, among all the properties that have been previously discussed, 
A) B) C) D) E)
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their great loading capacity is one of the main reasons for the growing popularity of MSM, since they 
were first proposed as DDS [62]. Thus, in this review, we overview the use of MSM acting as DDS in 
the field of bacterial infection treatment, summarizing their latest advances in combating planktonic 
bacteria, preventing biofilm formation and destroying the formed biofilm.  
2. Effect on Planktonic Bacteria  
As stated previously, the increasingly common resistance acquired from bacteria leads to 
higher doses and frequencies of antibiotics with the consequent side effects. The use of DDS emerges 
as a solution to protect the antibiotics, and to concentrate its action into the target bacteria, therefore 
improving its effectiveness. According to this, there are a number of different research groups who 
have chosen to study the increase in the effectiveness of different antibiotics after being loaded onto 
MSM. Since the number of published works on the loading and release of antibiotics on MSM [63–
66] is very extensive, we are only going to focus on those that include experiments with bacteria. A. J. 
Di Pasqua et al. conducted an experiment in which they synthesized mesoporous silica nanoparticles 
(MSNPs) with two different sizes, around 40 and 400 nm, and loaded them with tetracycline (TC), 
achieving a cargo of 18.7 and 17.7% (w/w), respectively. [67] After that, they compared the 
antibacterial capacity of both types of particles with the free drug against E. coli. The results showed 
that during the first few hours there were no differences in bacterial inhibition. However, after four 
hours, both types of particles proved to have a better antibacterial effect (Figure 3A). According to 
the authors, this may be due to the fact that by being inside the pores, the drug remains stable for a 
longer time. 
 
Figure 3. (A) Survival (%) of E. coli treated with a concentration: 1.0 µg/mL of tetracycline (TC) or its 
equivalent in loaded MSNPs; Adapted with permission from [67], copyright PUBLISHER YEAR. (B) 
Photographs of LB-agar plates coated with S. aureus (up) and E. coli (below) when supplemented 
with Ag/dendritic mesoporous silica nanoparticles (DMSNPs) loaded with CHX, CHX, AgNO3, 
Ag/DMSNPs, and DMSNPs, respectively. Adapted with permission from [68], copyright 
PUBLISHER YEAR. 
Polymyxin B (PolyB) is a potent antibiotic against resistant Gram-negative bacteria. However, 
its use is not as widespread as one might expect, since it also presents some toxicity in mammalian 
cells. A. Arpanaei et al. studied the biocompatibility and antibacterial efficacy of three different 
types of PolyB loaded MCM-41 MSNPs (bare, aminated, and carboxylated). The results 
demonstrated that loading the PolyB onto the nanoparticles did not improve the antibacterial 
capacity, but instead enhanced the biocompatibility of the free drug, especially for MSNPs that are 
incubated with HEK293 cells.[69] MSNPs have also been used to increase the effectiveness of some 
essential oils that demonstrate an antibacterial effect, according to reports by E. Andronescu et 
al.[70] 
MSM have an advantage in that we are able to obtain nanoparticles with different sizes and 
pore diameters through modifying the nature of the surfactant and synthesis conditions [71], 
meaning that they are able to load not only small molecules, but also larger proteins. C. Yu et al. took 
advantage of this possibility and synthesized dendritic mesoporous silica nanoparticles (DMSNPs) 
Time (h)
4 8 12 16 20 24
TC
MSNPs (≈400nm)
TC-MSNPs (≈400nm)
MSNPs (≈40nm)
TC-MSNPs (≈40nm)
Su
rv
iv
al
 (%
)
0
0
100
80
120
60
20
40
DMSNPsControl Ag/DMSNPs AgNO3 CHX Ag/DMSNPs
loaded with CHX
DMSNPsControl Ag/DMSNPs AgNO3 CHX Ag/DMSNPs
loaded with CHX
A) B)
S. aureus
E. coli
Pharmaceutics 2018, 10, x 6 of 30 
 
with different pore sizes, ranging from 2.7 to 22.4 nm.[72] These particles were loaded with 
lysozyme (lys), a natural protein that is able to cleavage the glycosidic bonds that are present in the 
cell wall of Gram-positive bacteria. As expected, the DMSNPs with the bigger pore diameter loaded 
higher amounts of lys (244.5 mg·g-1), compared with those that had a pore diameter of 2.7 nm, which 
loaded less amounts (37.6 mg·g-1). Due to the small size of the pores, the lys is only retained on its 
surface, and it relies on a kinetic release with a large initial burst. On the other hand, the larger pore 
samples showed a sustained kinetic effect over time. Finally, the in vitro antibiotic activity of 
lys-loaded MSNs was compared with free lys against E. coli bacteria. The free lys presented the 
highest Minimum Inhibitory Concentration (MIC), which was determined to be 2500 mg·mL-1, while 
the DMSNPs with bigger pores, presented the lowest MIC (500 µg·mL-1). In the same way, the NPs 
with a pore diameter of 22.4 nm proved to be those that produced greater long-term bacterial 
inhibition and that generated stronger damage in the bacterial wall, according to the SEM images. N. 
Sriranganathan et al. investigated the antibacterial capacity of gentamicin loaded biodegradable 
silica xerogel against mice infected with Salmonella enterica.[73] With the silica xerogel, there was a 
clear reduction in infection, both in the spleen and the liver, while no significant reduction was 
observed with the free drug. 
It has been demonstrated that loading antibiotics onto MSNPs produces certain improvements 
in the effectiveness of the drug. However, the chemical nature of MSM allows the surface to be 
modified according to its needs, providing these systems with greater versatility. Hence, by 
combining drug delivery systems, based on MSM with other antimicrobial agents, we can achieve an 
added value in bacterial eradication. It is well-known that some metals such as copper, silver, nickel, 
zinc, and others have quite strong antibacterial properties.[74,75] Based on this information, several 
groups have focused their research on the combination of some of these metals with silica 
nanoparticles. For example, in 2009 J. Zink et al. reported their findings on the antibacterial effect of 
silver nanocrystals, encapsulated in MSNPs.[76] According to their results, the silica coating reduced 
the hydrophobicity of the silver nanocrystals, decreasing their aggregation without compromising 
the oxidation of the silver crystals that were slowly released in the medium. To study the 
antimicrobial efficacy of the NPs, two different experiments were performed against two types of 
bacteria; Bacillus anthracis, and E. coli, (as Gram-positive and Gram-negative models, respectively). In 
the first one, three different concentrations of nanoparticles (20, 50, and 100 μg/mL) were added to 
the agar media, prior to its solidification. The suspension of bacteria was then spread onto the agar 
plates and incubated overnight. It was observed that the presence of the Ag-coated NPs in the agar 
prevented both types of bacteria from forming, and this was especially efficient for the B. anthracis, 
even with the smallest concentration. A second experiment studied the effect of the Ag-coated NPs 
on the bacterial growth kinetics in liquid media. The results showed that the nanoparticles did not 
produce any significant variation in the growth of E. coli; however, its presence slowed B. anthracis 
growth for the concentration of 50 μg/mL, and totally inhibited it at 100 μg/mL. In order to enhance 
the bacteria-nanoparticle interaction, the surface of the silica was functionalized with different 
polyelectrolytes, and it was observed that cationic NPs were more effective in slowing the growth of 
E. coli, while surface functionalization had almost no effect on B. anthracis. In 2017, Y. Zhou et al. 
went a step further and studied the synergistic bactericidal effect of loaded chlorhexidine, 
silver-decorated MSNPs against S. aureus and E. coli [68]. As can be observed in figure 3B, the 
combined treatment was more effective than AgNO3 or CHX separately against the E. coli and S. 
aureus bacteria. Finally, the biocompatiblity of the system was studied, showing cell mortality that 
was comparable to that of the controls, while the same concentrations of free CHX or silver ions were 
clearly toxic. J. Santamaría et al. performed a similar study, but loaded pereacetic acid into the 
mesopores of SBA-15, containing Ag NPs [77].  
Other metals whose antibacterial capacities have been studied in combination with silica are 
copper and nickel. M. Kooti et al studied the following complexes: Mesoporous silica 
copper-supported nanoparticles (MSNPs-SB-Cu), nickel (MSNPs-SB-Ni), and Schiff base (SB) [78]. 
After incubating four types of bacteria S. aureus, B. subtilis, E. coli, and P. aeruginosa into the presence 
of the particles, they observed that MSNPs-SB-Cu presented a bacteriostatic effect against E. coli and 
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S. aureus, and MSNPs-SB-Ni was bacteriostatic against E. coli, but bactericidal against S. aureus. The 
authors also loaded the nanoparticles with gentamicin and a performed disc diffusion assay. While 
non-loaded nanoparticles had almost no effect in any type of bacteria, the gentamicin loaded ones 
produced a similar halo of inhibition in all cases. A. Meghea et al. combined silica–titanium sieves 
(Si-Ti-Sv) with izohidrafural (Izo, a new antibacterial agent), and compared their antibacterial 
performance against different Gram-positive and Gram-negative strains isolated from urinary tract 
infections.[79] The results obtained showed, once again, that there is no universal treatment. 
Although in some cases, the combination of Izo-Si-Ti-Sv was the best option (Klebsiella pneumoniae 
and Proteus mirabilis) against Gram-positive cocci. The sieves without any load gave better results, 
and for most Escherichia coli strains, the directly administered antibiotic exhibited the highest power. 
Xiao et al. designed a multifunctional nanodevice that combined: i) MSNPs to load an antibiotic; ii) 
carbon dots (C-dots) to be visualized, and iii) Rose Bengal (RB), a photosynthesizer that generates 
ROS. Although initially designed for antitumor purposes, they proved that it was also effective as an 
antimicrobial agent, especially after loading ampicillin into its pores. The results showed that the 
combined effect of the antibiotic with the ROS was clearly more effective than any of them 
separately, especially for a concentration of 100 μg/mL, at which the population of E. coli was 
completely eradicated.[80] All the systems are summarized and referenced in Table 1. 
Table 1:  MSM in the treatment of planktonic bacteria. 
Type of device a Type of bacteria b Drug loaded (w/w %) c Ref. 
MCM-41 MSNPs E. coli Tetracycline (17.7–18.7%) [67] 
MCM-41 (MSNPs, N-MSNPs, C-MSNPs) E. coli, A. baumannii P. aeruginosa Polymyxin B (11.3–34.7%) [69] 
MCM-48 MSNPs S. aureus, E. coli, C. albicans 
EUC (7%), ORA (8%), CIN 
(41%) essentials oils 
[70] 
 DMSNPs E. coli Lysozyme (3.47–24.4%) [72] 
biodegradable silica xerogel S. enterica Gentamicin (31%) [73] 
MCM-41 Ag@MSNPs E. coli, B. anthracis Ag nanocrystals (-) [76] 
Ag/DMSNPs S. aureus, E. coli Chlorhexidine (10.6%) [68] 
SBA-15 Ag/MSNPs S. aureus Peracetic acid (5.3%) [77] 
MCM-41 (MSNPs-SB-Cu, MSNPs-SB-Ni) 
E. coli, P. aeruginosa, S. aureus,  B. 
subtilis Gentamicin (-) [78] 
MCM-41 Si-Ti-Sv 
E. coli, K. pneumoniae, M. 
morganii, P. mirabilis, E. faecalis 
Izohidrafural (6.8–30%) [79] 
DMSNPs@C-dots/RB E. coli Ampicillin (18.3%) [80] 
aMCM-41 MSNPs: Mesoporous silica nanoparticles with hexagonal mesoporous structure; N-MSNPs: aminated 
MSNPs; C-MSNPs: carboxylated MSNPs; MCM-48 MSNPs: MSNPs with cubic mesoporous structures; DMSNPs: 
MSNPs with a dendritic structure of pores; Ag@MSNPs: Nanoparticles with a silver core and coated with 
mesoporous silica; Ag/DMSNPs: DMSNPs decorated with silver NPs; SBA-15 Ag/MSNPs: Mesoporous silica 
nanoparticles with hexagonal mesoporous structures and microporous connections decorated with silver NPs; 
DMSNPs-SB-Cu: DMSNPs-supported copper, MSNPs-SB-Ni: MSNPs-supported nickel; Si-Ti-Sv: Silica–titanium 
sieves; MSNPs@C-dots/RB: carbon dots and Rose Bengal-embedded mesoporous silica nanoparticles. bE. Coli: 
Escherichia coli; A. baumannii: Acinetobacter baumannii; P. aeruginosa: Pseudomonas aeruginosa; S. aureus: 
Staphylococcus aureus; C. albicans: Candida albicans; S. enterica: Salmonella enterica; B. anthracis: Bacillus anthracis; B. 
subtilis: Bacillus subtilis; K. pneumoniae: Klebsiella pneumoniae; M. morganii: Morganella morganii; P. mirabilis: Proteus 
mirabilis; E. faecalis: Enterococcus faecalis. cEUC: eucalyptus; ORA: orange; CIN: cinnamon.  
2.1. Targeting Bacteria 
One of the main challenges in nanomedicine is being able to achieve a selective treatment that 
allows us to act exclusively on the target area, without affecting healthy tissues, thus reducing the 
side effects of the drugs. In cancer, the enhanced permeability and retention effect (EPR), also called 
“passive targeting” is very common.[81] Despite the fact that certain studies suggest there is also a 
presence of this effect in bacterial infection [82,83], its role is not as relevant or as efficient when 
concentrating the nanoparticles in the vicinity of the infection. Therefore, the existence of an “active 
targeting” is even more necessary, as it allows us to direct the particles to the correct place. In 
addition, intracellular infections require a great specificity of treatment[84], as the bacteria can 
outwit the immune system and resist the macrophage-mediated killing mechanism, by surviving in 
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its interior. In order to increase efficiency and selectivity of the antibiotic loaded nanoparticles, and 
to reduce the amount and frequency of the treatment, the surface of the MSNPs can be decorated 
with molecules that target bacteria, but that do not recognize the human host cells. The first 
difference between bacterial and human cells is that bacteria usually have a cell wall. The bacterial 
cell wall is a resistant and flexible layer that participates in the growth of the cell, and that allows it to 
withstand the osmotic force. It is composed partly of peptidoglycan and other glicolipids, exclusive 
of bacteria. The fact that human cells do not contain the same components means that these 
exclusive bacteria elements are the most important targets in bacteria.[49,85,86] Moreover, these 
components are so exclusive that they even differ, depending on the type of bacteria. Determined by 
the structure of its cell wall, bacteria are divided into two large groups: Gram-positive (G+) and 
Gram-negative (G-) (Figure 4).  
 
Figure 4: Comparison between structures and cell wall components of G+ and G− bacteria. Build 
upon the material available in the website https://smart.servier.com. 
G+ bacteria are surrounded by a double layer composed of the cytoplasmic membrane and a 
thick layer of peptidoglycan containing teichoic acids. In the case of G− bacteria, the protection is 
triple: the cytoplasmic membrane, a thin peptidoglycan layer, and an extra membrane called the 
outer membrane. In fact, this outer membrane is the reason of the greater resistance of G− bacteria 
against antimicrobial agents and antibodies. Instead of teichoic acids in the surface of the outer 
membrane, we find lipopolysaccharides as an exclusive component of G− bacteria. Therefore, by 
choosing the appropriate targeting molecule, it is possible not only to distinguish between human 
cells and bacteria, but to direct the nanoparticles to a specific type of bacteria. For instance teichoic 
acid antibodies or vancomycin can be used to target teichoic acids or peptidoglycan respectively in 
G+ bacteria and polymyxin can be used for selective targeting of the lipopolysaccharides of G− 
bacteria. [87–89]. 
Several studies show that for internalization, both types of bacteria appear to favor the presence 
of positive charges on the surface of nanoparticles.[90] M. Vallet-Regí et al. designed a novel 
nanovehicle, which was able to penetrate the cell wall of E. coli G- bacteria, due to the presence of 
policationic dendrimers on its surface.[91] Confocal microscopy experiments have shown that the 
functionalized nanoparticles have an enhanced degree internalization compared with the pristine 
ones (Figure 5, left side). The sample loaded with levofloxacin also demonstrated that it has a great 
antibacterial efficacy. It was also observed that the antibiotic power of Levo and the disruption 
capacity of the policationic dendrimer have a synergistic effect.  
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Figure 5. Left side: Confocal microscopy images of E. coli bacteria after treatment with (A) media, 
(B) pristine MSNPs, (C) N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (DAMO)-MSNPs, and 
(D) G3-MSNPs at 10 mg/mL with an incubation time of 90 min. The E. coli cell membrane was 
stained with FM4-64FX (red), and the MSNPs were previously functionalized with fluorescein 
(green). Adapted with permission from [91], copyright PUBLISHER YEAR.. Right side: TEM 
images of mycobacteria treated with Tre-hollow oblate mesoporous silica nanoparticles 
(HOMSNs) loaded with isoniazid (INH) for 0 hr (E), 0.5 hr (F), 1 hr (G), 2 hr (H), 4 hr (I), and 8 hr 
(J).; adapted with permission from [41], copyright PUBLISHER YEAR. 
A similar study against L. monocytogenes G+ was carried out by J. M. Barat et al.[92] Equivalent 
results were obtained when studying the effect of anchoring polyamines on the surface of MSNPs. 
Bacteria have some processes such as stress responses, virulence, etc., that are regulated by a 
two-component system, and that do not exist in human cells. As an example, histidine kinase 
autophosphorylation inhibitors (HKAIs) are efficient bactericidal agents, but they do not affect 
humans. Although in theory they should affect all bacteria, HKAIs have proven to kill G+ bacteria, 
but they have almost no effect on G−. This is probably as a result of the composition of the 
lipopolysaccharides that are present on the G− outer membrane that provide them with a great 
impermeability of hydrophobic antibiotics. To overcome this limitation, J. Wells et al. proposed the 
idea of capping HKAI-loaded MCM-41 NPs with ε-poly-L-lysine cationic polymer (ε-pLys).[93] 
Results demonstrated that the positive charge of the capped NPs gave rise to a bactericidal effect on 
the G−, which was comparable to that shown for the free HKAIs against G+ bacteria. Another 
difficulty that compromises the effectiveness of nanomedicine is the immune system, specifically the 
action of macrophages that tend to eliminate everything that is alien to the organism, including 
NPs.[94] To prevent this from happening, H. Wang et al. designed vancomycin-modified MCM-41 
NPs that selectively target and kill G+ bacteria over macrophage-like cells.[95] Vancomycin (Van) 
fulfills a double functionality: i) it inhibits the normal development of the cell wall, favoring bacterial 
death and ii) it targets G+ through specific hydrogen bonding interactions with the terminal 
D-alanyl-D-alanine moieties that are presented by this bacteria. Special mention should be given to 
the Mycobacterium genus, which falls within the G+ group, even though from an empirical point of 
view, they do not seem to be from this category, as their walls do not retain the dye responsible for 
their name. This is because the Mycobacterium cell wall is rich in mycolic acids, which gives it great 
strength. This unusual amount of mycolic acids has been used by M. Yan et al. as a distinguishing 
element to act precisely on this type of G+ bacteria.[41,96] First, they synthesized hollow oblate 
mesoporous silica nanoparticles (HOMSNs) and decorated them with trehalose (Tre) as a targeting 
molecule, and then loaded them with isoniazid (INH, an antimycobacterial drug that inhibits the 
synthesis of mycolic acid).[97] Trehalose is essential for mycobacteria, because it is one of the 
components that constitutes the mycolic acids and that participates in several transport processes 
through the cell wall.[98] As can be seen in Figure 5 (right side), after only 30 min of treatment the 
integrity of the mycobacteria appeared to be highly engaged. To test the targeting selectivity of Tre, 
A) B)
C) D)
E) F)
H) I)
G)
J)
MSNPs
G3-MSNPs
E. Coli CONTROL
DAMO-MSNPs
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two different experiments were performed: one substituting Tre for mannose as a control against 
Mycobacterium smegmatis; the second one exposed Tre-NPs to two different strains of G− E. coli and G+ 
S. epidermidis bacteria. Both internalization and death were either non-existent, or much lower than 
that obtained for Tre-HOMSNs in M. smegmatis. 
Table 2: Targeted MSNPs for the treatment of planktonic bacteria 
Targeting molecule a Type of bacteria b Drug loaded (w/w %) c Type of device d Ref. 
Gram negative     
G3 E. coli  Levofloxacin (3.2–7.8%) MCM-41 G3-MSNPs [91] 
ε-pLys E. coli HKAIs (0.5–13.8%) MCM-41 ε-pLys-MSNPs [93] 
Gram positive     
Vancomicin S. aureus Vancomicin (anchored)(50%) MCM-41 Van/MSNPs [95] 
Trehalose M. smegmatis INH (56.3–63.6%) Tre-HOMSNs [41] 
a G3: polycationic dendrimer, poly(propyleneimine) dendrimer of the third generation; ε-pLys: ε-poly-L-lysine 
cationic polymer. b E. coli: Escherichia coli; S. aureus: Staphylococcus aureus; M. smegmatis: Mycobacterium smegmatis. 
cHKAIs: histidine kinase autophosphorylation inhibitors; INH: isoniazid; d MCM-41 G3-MSNPs: MCM-41 type 
MSNPs functionalized with G3; MCM-41 ε-pLys-MSNPs: MCM-41 type MSNPs functionalized with ε-pLys; 
MCM-41 Van-MSNPs: MCM-41 type MSNPs functionalized with vancomycin; Tre-HOMSNs: 
Trehalose-functionalized hollow oblate mesoporous silica nanoparticles. 
2.2. Stimulus-Responsiveness 
Despite the fact that MSM have demonstrated they are good as drug delivery agents, often, 
these nanocarriers have also shown the premature release of cargo molecules. However, as 
mentioned above, by being able to functionalize the surface of silica materials, this allows us to 
incorporate polymers or other molecules in order to temporarily block the pores of the nanocarriers, 
thus achieving a well-controlled release of the therapeutic agents. These temporary gates are 
considered to be “smart”, since they only open after the application of a stimulus that can be both 
internal and external. Nowadays, it is a very popular approach to use stimulus-responsive MSN for 
the treatment of cancer.[99–101] Although the use of these smart particles to treat bacterial infection 
is not so widespread, we can find some examples of its application in literature.[102]  
Several studies have demonstrated that bacterial infections are related to a decrease in the 
environmental pH, in anaerobic conditions.[103,104] If the multiplication process of the bacteria is 
strongly active during infection, it can result in the depletion of oxygen resources. This forces 
bacteria to obtain energy through an anaerobic metabolism, which, during the process, produces 
organic acids. Based on that, studies on the release of antibiotics from coated-MSNPs have been 
carried out according to the pH [105]. C-H. Lee et al. designed a silver−indole‑3 acetic acid complex 
(IAAH) based on IBN-4 silica nanoparticles, which was able to release Ag ions under acidic 
conditions.[106] Apart from the well-known antimicrobial activity of the silver ions [107,108], a few 
years ago, it was also reported that Ag+ can generate ROS, which induce membrane damage and 
provide the sought-after bactericidal capacity.[109] The efficacy of these Ag-IAAH-MSNPs was 
studied against different types of bacteria; both in the planktonic state once the biofilm was formed, 
and even in vivo, obtaining, in all cases, very promising results, which demonstrate the potential of 
this system for the treatment of bacterial infection. 
In 2015 J. Zink et al. proposed using pH sensitive MSNPs, loaded with moxiﬂoxacin (MXF) to 
treat the F. tularensis infection. [110] The opening mechanism was based on a two component system; 
1-methyl-1H-benzimidazole (MBI) stalk covalently attached to the MSN’s surface, which at a 
physiological pH holds the cyclodextrin (CD) caps during hydrophobic interactions. After being 
internalized by the cells, at the acidic pH of the endosomes the stalk is protonated and the binding 
affinity between the two elements drastically decreases, leading to the cargo release. Due to how 
MSNPs are avidly internalized by macrophages, the use of this device for tularemia treatment is 
very advantageous and such cells are one of the primary targets for F. tularensis. The in vivo efficacy 
of the device was then tested in a mouse model, of pneumonic tularemia. The results showed that 
without treatment, the mice rapidly feared signs of infection, while those treated had a healthier 
appearance and the bacterial presence in their organs was much lower (Figure 6A). 
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Figure 6: (A): In vivo efficacy of 1-methyl-1H-benzimidazole (MBI)-MSNPs loaded with 
moxiﬂoxacin (MXF), assessed by an assay of F. tularensis burden in the mouse organs. Post-infection, 
mice were treated with free MXF or with MXF-loaded MBI-MSNPs by tail vein injection on days 1, 3, 
and 5. Mice were euthanized one day after the last dose of treatment (day 6) to enumerate the 
bacterial numbers in the lung, liver, and spleen. Adapted with permission from [110]. (B) Schematic 
representation of the triggered release of cargo due to a competitive displacement of the antibody 
(green) that caps the pore by naturally occurring F. tularensis lipopolysaccharide (LPS) (blue). 
Adapted with permission from [111], copyright PUBLISHER YEAR. 
Other than the pH, other stimulus has also been used for the controlled release of drugs in the 
treatment of bacterial infection. T. Tang conceived a MCM-41 based nanodevice that is able to 
release their cargo in the presence of bacterial toxins.[56] After loading it with gentamicin (Gen), to 
avoid premature release, the MSNPs were coated with a liposome bilayer (L). However, at infection 
sites the presence of bacterial phosphatases, lipases, and phospholipases degraded the liposomes, 
allowing for the controlled release of Gen. In addition, to achieve an even more effective treatments, 
the liposome bilayer was functionalized with UBI29−41 (U), an ubiquicidin peptide for bacteria 
targeting. Having achieved good results against bacteria, the system was then studied in vivo in S. 
aureus-infected mice. Data demonstrates the excellent target efficiency of UL-MSNPs, as well as their 
antibiotic activity, compared with the Gen treatment. 
According to the authors’ opinions, and despite being a preliminary study, a potential effective 
approach in terms of controlled drug release is that adopted by J. Zink. In this system, which 
combines targeting and the stimulus-response sensitivity, the binding to the bacterium itself is what 
triggers the release of the drug, [111] thus increasing the selectivity of the treatment. The pores of 
MCM-41 MSNPs were blocked with FB11, an antibody for lipopolysaccharide (LPS) that is present 
in the Francisella tularensis (Ft) bacteria wall. To link the caps, a derivative (with a reduced affinity) of 
the O-antigen of Ft LPS (modified Ft LPS) was immobilized onto the surface of the nanoparticles. 
Thereby, FB11 targets the nanoparticles towards the bacteria, and once on its surface, the presence of 
the native antigen Ft LPS, which has a greater affinity for the antibody, displaces the modified one. 
This causes the pores to open, and therefore release the load. The authors used a dye to incubate the 
Ft and Francisella novocida (Fn) with the nanoparticles and compared the fluorescence levels after 1 
hr. They observed that the intensity detected in Ft was 100 a.u., while the value for Fn was only 20 
a.u, which provides large selectivity of the nanoplatform in vitro. 
Table 3: Stimuli-responsive MSNPs for the treatment of planktonic bacteria 
Stimuli a Type of bacteria b Drug loaded (w/w %) c Type of device d Ref. 
pH 
E. coli, B. subtilis, S. aureus, 
 S.epidermidis 
Ag+ (70%) IBN-4 IAAH-MSNPs  [106] 
pH 
F. tularensis, F. 
tularensis-infected mice 
Moxifloxacin (51.4%) MCM-41 MBI-MSNPs  [110] 
Bacterial toxins 
S. aureus, S. aureus-infected 
mice 
Gentamicin (25.6%) MCM-41 UL-MSNPs [56] 
antigen Ft LPS F. tularensis, F. novocida Hoechst (-) 
MCM-41 FB11-mFt 
LPS-MSNPs 
[111] 
A) B)Control
MXF 50 μg
MXF 100 μg
MXF 200 μg
MBI-MSNPs MXF 
loaded (50 μg)
LiverLung Spleen
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a Ft LPS: LPS present in F. tularensis (Ft). b E. coli: Escherichia coli; B. subtilis: Bacillus subtilis; S. aureus: Staphylococcus 
aureus; S. epidermidis: Staphylococcus epidermidis; F. tularensis: Francisella tularensis. c IBN-4 IAAH-MSNPs: 
Silver−Indole‑3 Acetic Acid Complex based on IBN-4 silica nanoparticles; MCM-41 MBI-MSNPs: 
1-methyl-1H-benzimidazole functionalized MSNPs with MCM-41 structure; UL-MSNPs: MSNPs coated with a 
liposome bilayer and functionalized with the ubiquicidin peptide (UBI29−41); FB11-mFt LPS-MSNPs: MSNPs 
functionalized with an antibody for Ft LPS through a derivative of the O-antigen of Ft LPS. 
3. Effect on Biofilms 
As previously mentioned, a biofilm is an assembly of microorganisms that grow strongly 
connected to a surface and are protected by a matrix of primarily polysaccharide material [112]. The 
complexity of the biofilm can be variable, as it can be a comprise of a single microbial species, or a 
combination of different ones [113]. Regardless of the species, the formation of the biofilm is the 
result of a sequence of phenomena [114]. First, the bacteria is adhered to a surface, then there is the 
proliferation and differentiation stage, during which the bacteria begin to secrete an 
exopolysaccharide. This constitutes the extracellular matrix and culminates with dispersion, where 
some bacteria leave the initial focus of infection in order to colonize new surfaces [115]. The adhesion 
of bacteria to a surface as a means of protection is the most accepted explanation for biofilm 
formation. The main challenge of biofilm formation is that bacteria acquire a greater tolerance to 
both the antibiotics and the response of the immune system. While in the planktonic state, all 
bacteria are exposed to the presence of biocides or immune cells, in the biofilm, bacteria are 
structurally organized in such a way that only the external ones, which are also protected by the 
polysaccharide matrix, receive this action.[113] Although the polysaccharide matrix acts as a first 
physical barrier, there are other reasons for why biofilms acquire greater tolerance to antibiotics 
[116]. These include: i) the presence of other components in the matrix such as bacterial and host 
DNA and bacterial proteins that bacteria can use to their own benefit, for instance, increasing the 
shielding capacity of the matrix even more [117]; ii) a population of bacteria with a varied 
physiology, especially in terms of growth states, that present different sensitivities to the same 
treatment [118]; iii) the development of specific protective tools such as efflux pumps [119]; iv) the 
synthesis of antibiotic-degrading enzymes [120]; v) the establishment of a bacteria–bacteria 
communication, also known as quorum sensing [121]; and vi) an active adaptation of the 
microenviromental limitations [122].  
In addition to all these defense mechanisms, even after being damaged, the biofilm has the 
capacity to reconstruct again if it was not entirely eliminated [123]. Due to its complexity and the 
serious consequences of its appearance, it is not difficult to understand why in the last few years the 
number of studies that are focused on both preventing and treating bacterial biofilm formation has 
increased considerably.  
3.1. Prevention of Biofilm Formation 
Since the first phase of biofilm formation is bacterial adhesion, much effort has been focused on 
understanding the factors that affect this process. The surfaces to which the bacteria can adhere are 
very varied, including wounds, implantable devices, and even one another [122]. However, biofilms 
are produced preferentially in certain parts of the body (such as the urinary tract [124,125], mitral 
valves [126], lungs [127], or the middle-ear (especially in children) [128,129]) and implanted devices. 
Although infections in our own tissues are difficult to prevent, it is possible to minimize the number 
of infections that are associated with implants. Nowadays medical aids allow us to implant diverse 
materials into the organism to improve the quality of life of the patients [127,130]. Although these 
materials have been made biocompatible and they therefore do not cause adverse reactions or 
rejections by the immune system, the introduction of a foreign element into the body generates an 
optimal niche for the formation of a biofilm. Some of the most common implants for where the 
formation of the biofilm takes place are: dental implants, heart valve implants or pacemakers, and 
other implants of the hip [131–133]. The appearance of infections are also frequent after the use of 
temporary or partial implantation devices, such as catheters. 
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To avoid that, the scientific interest aimed at developing biomaterials that are less susceptible or 
even resistant to bacterial infections has significantly increased in recent years [134–137]. So far, 
different strategies have been used for this purpose (Figure 7): (i) loading/functionalizing the 
material with antimicrobial substances [138], (ii) biomaterial surface modification to give 
anti-fouling capabilities [139–141], (iii) combining antifouling and antimicrobial effects in the same 
coating [142,143].  
 
Figure 7: Current strategies for developing biofilm-resistant biomaterials. (A) 
Antimicrobial-loaded/functionalized materials; (B) antifouling materials due to (B1) hydrophilic or 
(B2) superhydrophobic surfaces; (C) combining antifouling and antimicrobial effects in the same 
material. 
If we focus on the use of porous silica materials as a way to prevent the formation of the 
bacterial biofilm, we can highlight the following advances, which are also summarized in Table 4.  
Several studies have demonstrated that loading an antimicrobial agent onto silica pores can 
reduce biofilm formation, since the release of the drug eliminates the surrounding bacteria and their 
adhesion to the surface of the material [70,77,144–147]. Thus, these materials could be good 
candidates for covering other surfaces that are more susceptible to being colonized by bacteria. M. C. 
Chifiriuc et al. used cephalosporin (Ceph)-loaded MCM-48 MSNPs as an implant coating to prevent 
microbial biofilm formation [148]. They observed that for the coated samples, the sustained release 
of Ceph rested on a significant reduction of E. coli biofilm formation, especially during the first 24 hr. 
P. Behrens et al. coated the implant surfaces with a layer of ciprofloxacin (Cip)-loaded mesoporous 
silica. They then investigated the effect of the sulfonic acid functionalization of the pores on the 
drug-loading process [149]. In addition, the authors managed to extend the Cip release time by up to 
60 days by adding successive silica derivative layers. When tested against P. aeruginosa bacteria, the 
sulfonate-functionalized material, which was loaded with Cip and then modified with 
bis(trimethoxysilyl)hexane, showed the best anti-biofilm capacity. Recently, A. Yu et al. performed a 
similar study, but loaded gentamicin (Gen) onto the silica pores, and used a Nafion layer to slow 
down the Gen release and prolong its antibacterial activity for more than two months [150]. The use 
of dental implants is a very common practice in our days. However, the appearance of infection after 
surgery still occurs at a significant rate. Due to its lightness, its resistance, and especially its 
biocompatibility, titanium is one of the most commonly used materials in implants of all types, 
including dental. However, bacteria easily adhere to their surface, causing implant failure. To avoid 
this, several groups have developed new composite coatings that combine other materials (usually 
Antifouling surfaces Antimicrobial and 
antifouling surfaces
Antimicrobial surfaces
Superhydrophobic surfacesHydrophilic surfaces
A) B) C)
B1) B2)
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polymers) with drug-loaded silica NPs [151,152]. In all studies, these coatings demonstrate that they 
are able to provide a strong antimicrobial capacity to the titanium surface, both reducing the biofilm 
formation and killing the bacteria near the surface. Poly(methyl methacrylate) (PMMA) is another 
material widely used in dental clinics, which has been modified with nanomaterials to improve its 
antibacterial properties [153]. R. Tan et al.[154] and H-H. Lee et al.[155] studied the effect of adding 
drug loaded silica NPs to PMMA. Both observed a clear enhanced antibacterial effect compared with 
the pure PMMA, while the mechanical properties of the material were negligibly affected. Other 
cement materials combined with silica NPs have also demonstrated great results in avoiding biofilm 
and caries formation [156,157].  
It is well known that bacteria and other microorganisms tend to adhere to a surface due to the 
presence of hydrophobic interactions [158]. Therefore, reducing these interactions by making the 
surface of the material more hydrophilic reduces the probability of biofilm formation. It is 
considered that the non-stick ability of hydrophilic materials is closely related to a hydration layer 
formed close to the surface [159]. Its presence may hinder the approximation of bacteria to the 
material surface and therefore, decreases the likelihood of its irreversible adhesion and the 
formation of the biofilm. Agarose; an hydrophilic polymer[160] derived from agar, was incorporated 
into silica NPs and used as an antifouling coating for silicone biomaterials. J. Shen et al. observed 
that loading agarose and heparin into the same system allowed them to achieve a coating with a 
double functionality: antifouling and anticoagulant [161]. The results showed a decrease in bacterial 
adhesion, due to the presence of agarose and an absence of platelets, due to the anticoagulant action 
of the released heparin (Figure 8).  
 
Figure 8: SEM images of (A) Silicone film (Si), (B) MSNPs coated Si (MSNPs-Si), (C) 
Agarose-incorporated MSNPs-Si (AMSNPs-Si), and (D) Heparin-loaded AMSNPs-Si, respectively 
(HAMSNPs-Si). The static water contact angle of (E) Si, (F) MSNPs-Si, (G) AMSNPs-Si, and (H) 
AHMSNPs-Si. SEM images of (I-L) S. aureus and (M-P) E. coli cultured on (I and M) Si, (J and N) 
MSNPs-Si, (K and O) AMSNPs-Si, and (L and P) AHMSNPs-Si, respectively. Adapted with 
permission from [161], copyright PUBLISHER YEAR. 
Another strategy that was used to design hydrophilic materials involves the synthesis of 
zwitterionic surfaces. Zwitterionic materials are those that present the same number of positive and 
negative charges on its surface, thus preserving the electrical neutrality.[162] When talking about 
obtaining zwitterionic silica materials, there are several strategies that can be summarized: i) 
functionalization with zwitterionic elements, or ii) anchoring mixtures of molecules whose net 
average charge is zero. [55] M. Vallet-Regí et al. designed the first porous silica material with 
zwitterionic character at physiological pH.[143] The surface was functionalized with 
(N-(2-aminoethyl)-3-aminopropyltrimethoxysilane) (DAMO). This alkoxysilane presents primary 
C)
A)
D)
B)
C) D)
E) F)
G) H)
I) J)
K) L)
M) N)
O) P)
100 nm 100 nm
100 nm 100 nm
10 μm 10 μm
10 μm 10 μm
10 μm 10 μm
10 μm 10 μm
121.3 ± 2.9° 95.6 ± 3.9°
51.3 ± 2.4° 37.5 ± 2.9°
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and secondary amines that are positively charged at pH 7.4, which, in combination with the negative 
charge characteristics of the silanols, provided the desired zwitterionic character. In addition, the 
pores were loaded with cephalexin to achieve a sustained release that killed the surrounding 
bacteria. Therefore, they took advantage of the properties of the SBA-15 to design a new material 
with dual antibacterial capability against S. aureus.  
We have mentioned that while hydrophilic surfaces repel bacterial adhesion, hydrophobic 
surfaces favor it. However, numerous studies show that achieving an extreme hydrophobic 
character, known as “superhydrophobicity”, re-equips the materials with antifouling 
properties.[163–166] A superhydrophobic material is one that is very difficult to wet.[167] The lotus 
leaf is the most representative example, as the contact angle of water is over 150°.[168] It is believed 
that its “unwettability” is due to micro/nanosized roughness, and to a hierarchical structure.[169] 
Since the size of the bacteria is in the same order of magnitude, the effects of nanoscale features that 
also affect surface energy, have shown that they influence the binding processes.[164] Therefore, by 
using superhydrophobic materials, it is possible to reduce the bacteria–surface adhesion forces, 
hindering their union, facilitating their removal, and limiting biofilm formation.[170] C. Wu et al. 
synthesized Ag-supported mesoporous silica microcapsules and incorporated them into a 
hydrophobic fluoro-silicone resin, forming a rougher nanostructure. [171] Results showed that this 
new material reached an antibacterial rate of 99.3%, because of the combination of action of released 
silver ions and a superhydrophobic surface (Figure 9).  
 
Figure 9: SEM images of (A) the MSMAs/FSR ﬁlm; (B) the cross-sectional structure of the ﬁlm. 
Antibacterial activities of various samples against E. coli in diﬃerent initial bacterial concentrations: 
(C) the blank (without ﬁlm); (D) the control (with the pure FSR ﬁlm); (E) the sample (with the 
MSMAs/FSR ﬁlm). Adapted with permission of The Royal Society of Chemistry [171].  
Table 4: MSM for preventing biofilm formation. 
Strategy  Type of bacteria a Drug loaded (w/w %) b  Type of device c Ref. 
Antimicrobial effect 
S. aureus, E. coli, C. 
albicans 
EUC (7%), ORA (8%), CIN 
(41%) essentials oils 
MCM-48 MSNPs [70] 
Antimicrobial effect S. aureus  Peracetic acid (5.3%) SBA-15 Ag/MSNPs [77] 
Antimicrobial effect S. aureus, S. epidermidis 
Vancomycin (−), 
Rifampin (−) 
SBA-15 MSNPs [144] 
Antimicrobial effect E. coli Cephalosporin (−) MCM-48 MSNPs [148] 
Antimicrobial effect P. aeruginosa Ciprofloxacin (2 µg·cm−2) LMU-1 bth@MSNPs [149] 
Antimicrobial effect S. aureus  Gentamicin (21.9%) MCM-41 Nafion@MSNPs [150] 
Antimicrobial effect S. aureus Gentamicin (−) Gel/SiO2-Gen NP-coated Ti [151] 
Antimicrobial effect A. actinomycetemcomitans Ag NPs (4.26%) AgNP/NSC-coated Ti [152] 
Antimicrobial effect S. aureus Gentamicin (−) SBA-15 PMMA/MSNPs [154] 
Antimicrobial effect C. albicans, S. oralis Amphotericin B (2.5–7.2%) MCM-41 PMMA/MSNPs [155] 
A)
B)
C)
D)
E)
2 μm
1 μm
10 3 CFU 10 2 CFU
10 3 CFU 10 2 CFU
10 3 CFU 10 2 CFU
10 1 CFU
10 1 CFU
10 1 CFUsample
control
blank
Pharmaceutics 2018, 10, x 16 of 30 
 
Antimicrobial effect S. mutans EGCG (11.29%) MCM-41 nHAp@MSNPs [156] 
Antimicrobial effect S. mutans Chlorhexidine (44.62%) pMCM-41-GIC [157] 
Anti-fouling effect E. coli, S. aureus Heparine (5.7%) AMSNPs-Si [161] 
Anti-fouling and 
antimicrobial effects 
S. aureus Cephalexin (1.2%) SBA-15 DAMO-MSN [143] 
Anti-fouling and 
antimicrobial effects 
E. coli Ag NPs (20.34%) MSMAs/FSR film [171] 
a S. aureus: Staphylococcus aureus; E. coli: Escherichia coli; C. albicans: Candida albicans; S. epidermidis: Staphylococcus 
epidermidis; P. aeruginosa: Pseudomonas aeruginosa; A. actinomycetemcomitans: Aggregatibacter actinomycetemcomitans; 
S. oralis: Streptococcus oralis; S. mutans: Streptococcus mutans. b EUC: eucalyptus; ORA: orange; CIN: cinnamon; 
EGCG: epigallocatechin-3-gallate, a polyphenolic compound extracted from tea leaves that exhibits antibacterial 
activity. c SBA-15 Ag/MSNPs: Mesoporous silica nanoparticles with hexagonal mesoporous structures and 
microporous connections decorated with silver NPs; LMU-1 bth@MSNPs: bis(trimethoxysilyl)hexane 
(bth)-coated MSNPs with non-ordered pores; Nafion@MSNPs: Nafion-coated MSNPs;  Gel/SiO2-Gen NP-coated 
Ti: titanium surface coated with a composite made of gelatin and “gentamicin-rich nuclei” silica nanoparticles; 
AgNP/NSC-coated Ti: titanium surface coated with a silica-based composite coating containing silver 
nanoparticles; SBA-15 PMMA/MSNPs: poly(methyl methacrylate) resin containing SBA-15 MSNPs; MCM-41 
PMMA/MSNPs: poly(methyl methacrylate) resin containing MCM-41 MSNPs; MCM-41 nHAp@MSNPs: 
nanohydroxyapatite/mesoporous silica nanoparticles; pMSN-GIC: glass ionomer cement containing 
expanded-pore MCM-41 MSNPs; AMSNPs-Si: (agarose-loaded mesoporous silica nanoparticles) coating 
immobilized on silicone films; SBA-15 DAMO-MSN: SBA15 material functionalized with 
(N-(2-aminoethyl)-3-aminopropyltrimethoxysilane); MSMAs/FSR film: mesoporous silica microcapsules with 
AgNPs supported onto the interior walls incorporated onto the hydrophobic fluoro-silicone resin. 
3.2. Effect on the Formed Biofilms 
Without any doubt, the best option is to try to avoid biofilm formation with any of the 
aforementioned strategies or materials. However, if it has already been formed, and taking into 
account how difficult it is to completely eliminate a biofilm, nowadays, the most effective procedure 
is to eliminate the infected area or device [172,173]. However, this is a great inconvenience for 
patients, and carries a high hospitalization cost, not to mention that in some cases, it is not possible 
to remove.[174] As far as we are concerned, the most promising alternative to surgery involves the 
disruption of the biofilm to make it more vulnerable to the action of the antibiotics and the immune 
system. Recently, some groups have reported the use of small molecules [175], metal nanoparticles 
[176], bacteriophages [177], or enzymatic lysis [178] as methods for destroying the biofilm matrix 
backbone. Investigations have also been carried out into the efficacy of targeting [179] biofilms by 
the modification of the nanoparticles surface, by covalently attached antibodies [180], dendrimers 
[181,182], or lectins [183].  
In this sense, the use of MSM as DDS that are capable of disrupting and penetrating into the 
biofilm and once there releasing their cargo, to increase their antimicrobial efficiency, has great 
potential. These type of studies have recently begun, and therefore, the number of publications on 
this subject is limited. Q. Ye et al. reported their use of rod shaped hollow MSNs loaded with 
lysozyme (HMSN-LP@Lys) to act inside the biofilm.[184] A clear increase in bacterial killing 
capability was observed for HMSN-LP@Lys compared with that obtained for the free drug. 
Additionally, the biocompatibility of the device was tested towards mammal cells, with the 
achievement of around 80% survival. Several studies performed by M. Vallet-Regí et al. 
demonstrated that the presence of positive charges on the surface of the silica NPs not only favors 
the affinity and disruption of the bacterial wall, but also of the feared biofilm. Thus, MCM-41 silica 
NPs were loaded with levofloxacin (Levo, a wide range fluoroquinolone antibiotic) and 
functionalized with the amino group containing molecule 
N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (DAMO)[185]. To test the targeting effect, grown 
biofilms were exposed to both functionalized and non-functionalized particles. Confocal images 
showed that while DAMO decorated NPs (D-MCM-41) internalized inside the biofilm, the bare ones 
remained mostly on the surface. When the biofilm were exposed to the loaded nanoparticles, a clear 
reduction of the biofilm was observed for that treated with Levo@D-MCM-41. However, for those 
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treated with Levo@MCM-41, a remaining layer persisted. In another study, the MCM-41 were 
functionalized with a poly(propyleneimine) third-generation dendrimer (G3), richer in amino 
groups.[91] In this case after adding Levo@G3-MCM-41 the biofilm was totally destroyed (Figure 
10A–D).  
 
Figure 10. (A–D) Confocal microscopy study of the antimicrobial activity of the Levo-loaded MSNPs 
materials onto Gram-negative E. coli biofilm. Live bacteria are stained in green, dead bacteria in red, 
and the matrix biofilm in blue. Adapted with permission from [91], copyright PUBLISHER YEAR. 
(E–H) Characterized bacteria-driven biohybrid micro-swimmers. (E) SEM image of MSR-1 
bacterium. Inset displays TEM of MSR-1 and the internal magnetosome chain. Inset scale bar = 500 
nm. (F) TEM image of pores in MSMi. Inset displays bright field microscopy images of long and short 
MSMi. Inset scale bar = 10 μm. (G) SEM of MSR-1 cells captured within a microtube. Inset displays 
increased magnification of bacteria in the tube. Inset scale bar = 500 nm. (H) Bright field microscopy 
images of MSR-1-powered biohybrids swimming. Blue arrow indicates location of MSR-1 inside the 
microtube. Red track indicates the trajectory of the biohybrid. Adapted with permission from [186], 
copyright PUBLISHER YEAR. 
In 2017, S. Sánchez et al. proposed the use of bacteria as a new method of transport for 
mesoporous silica microtubes (MSMi) into the biofilm.[186] Magnetosopirrillum gryphiswalense 
(MSR-1) are nonpathogenic magnetotactic bacteria (Figure 10E) that are capable of being guided 
under the action of low magnetic fields. MSMi (Figure 10F) with the appropriate size to harbor 
MSR-1 inside (Figure 10G) were synthesized and loaded with ciprofloxacin, an antibiotic that is 
soluble only under acidic conditions. Results demonstrated that they were able to guide the 
MSR-1/MSMi biohybrid to the biofilm, and to force its penetration by magnetic action (Figure 10H), 
allowing the release of the cargo by the presence of acidic conditions, once internalized. 
Table 5: MSN for the treatment of the formed biofilm. 
Targeting 
molecule a 
Type of bacteria b Drug loaded (w/w %) Type of device c Ref. 
- E. coli Lysozyme (35%) HMSN-LP [184] 
- S. aureus Ag+ (70%) IBN-4 IAAH-MSNPs [106] 
DAMO E. coli, S. aureus Levofloxacin (3.2–5.0%) MCM-41 DAMO-MSNPs [185] 
G3 E. coli Levofloxacin (3.2–7.8%) MCM-41 G3-MSNPs [91] 
MSR-1 E. coli Ciprofloxacin (−) MSR-1/MSMi [186] 
a DAMO: N-(2-aminoethyl)-3-aminopropyltrimethoxysilane; G3: poly(propyleneimine) third-generation 
dendrimer; MSR-1: Magnetosopirrillum gryphiswalense. b E. coli: Escherichia coli; S. aureus: Staphylococcus aureus; c 
HMSN-LP: rod shaped hollow MSNPs with large cone shaped pores; IBN-4 IAAH-MSNPs: Silver−ondole‑3 acetic 
acid complex based on IBN-4 silica nanoparticles; MCM-41 DAMO-MSNPs: MCM-41 type MSNPs functionalized 
A) B)
C) D)
Levo-MSNPs
Levo-G3-MSNPs
E. Coli CONTROL
Levo-DAMO-MSNPs
E)
G)
F)
H)
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with DAMO; MCM-41 G3-MSNPs: MCM-41-type MSNPs functionalized with G3; MSR-1/MSMi: Mesoporous 
silica microtubes (MSMi) with MSR-1 inside. 
4. Drawbacks 
Despite the numerous advantages that the use of MSM as DDS entails for the treatment and 
prevention of bacterial infection, the use of these materials also has certain disadvantages.  
Some of them are general for all nanoparticles, regardless of their nature. One of them is related 
to its aggregation in vivo, while in vitro studies offer good results, the complexity of the medium in 
vivo can affect the stability of the particles in suspension, altering its effectiveness. Another one is 
the reproducibility, which, since it is not perfect, requires that each batch must be individually 
characterized and tested. Perhaps because of this, similar particles provide contradictory results in 
different studies. In addition, each modification made in the nanoparticle can have potential 
repercussions on cells and bacteria, so that it is considered to be a different system that has to be 
re-characterized, greatly increasing the number of experiments, and delaying the time necessary for 
it to be used under clinical conditions. In addition, the more complex the system, the more difficult it 
is to understand its method of action, because it can have several antibiotic/toxic effects at the same 
time. 
Specifically for MSM, although it has been seen that they are biocompatible, some studies 
suggest that their use can produce hemolysis, because of the interaction of silanol groups with the 
phospholipids present in the membrane of red blood cells. However, more studies are needed to 
know the real impact of these materials on the body in the long term. 
5. Conclusions and Future Outlook 
After analyzing this bibliographic work, it is clear that drug delivery systems based on porous 
silica materials have a great potential in the treatment of bacterial infection. Although we have come 
a long way, there is still a lot of research to be done since certain aspects, such as stimulus–response 
systems or biofilm targeting, have only just begun to be studied. As stated above, so far, there is no 
universal treatment that is perfect on its own. However, a great advantage of MSM are their ability 
to be combined with other materials, thus achieving new and improved properties, and therefore a 
multifunctional applications. Thus, as mentioned in the title, the authors consider that mesoporous 
silica materials could be the definitive solution to bacterial infection, since they can attack it via 
numerous routes, not only those based on drug delivery that have been widely described in this 
manuscript, but also those that can be used for detection, as adjuvants, etc.  
We believe it is necessary to carry out further development of new antibacterial MSM, paying 
particular attention to their functionalization with specific biomolecules (e.g. antibodies, biomarkers 
etc.) for controlled specific targeting of pathogenic bacteria. This is particularly of great importance 
in medicine, as one major drawback of many current therapies is the problem of getting the drug 
into the site of interest. In addition, MSM present an excellent substrate and matrix for the 
development of new drug delivery systems with so-called “on demand” drug release. This could be 
achieved by loading pores with selected antibacterial drugs, and then by closing pores with 
appropriate “nano-plugs”, which could then be opened using light (e.g. quantum dots or large dye 
molecules), chemical (e.g. pH dependent cleavage) or magnetic (e.g. magnetic nanoparticles) 
initiation. This area is still to be developed; therefore, further research and the design of new 
materials and approaches for MSM preparation and modification will be highly important for future 
applications of these materials in biology and medicine. However, all these efforts will be in vain, 
unless society begins to use the treatments more carefully and responsibly. Currently the use of 
nanoparticles seems to be an effective alternative to treat bacterial infection, but if used abusively, 
the bacteria could potentially develop defense mechanisms and resistance against them. 
Abbreviation 
A. actinomycetemcomitans: Aggregatibacter actinomycetemcomitans 
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A. baumannii: Acinetobacter baumannii 
AFM: Atomic force microscopy  
Ag/DMSNPs: DMSNPs decorated with silver NPs 
Ag@MSNPs: Nanoparticles with silver core and coated with mesoporous silica 
AMSNPs-Si: (Agarose-Loaded Mesoporous Silica Nanoparticles) Coating Immobilized on Silicone Films 
B. anthracis: Bacillus anthracis; 
B. subtilis: Bacillus subtilis 
bth: bis(trimethoxysilyl)hexane  
C. albicans: Candida albicans 
CD: Cyclodextrin 
C-dots: Carbon dots  
Ceph: Ccphalosporin 
CFU: Colony Forming Units 
CIN: cinnamon 
Cip: Ciprofloxacin 
C-MSNPs: carboxilated MSNPs 
DAMO: N-(2-aminoethyl)-3-aminopropyltrimethoxysilane  
DDS: Drug delivery systems  
DMSNPs: Dendritic mesoporous silica nanoparticles  
DMSNPs-SB-Cu: DMSNPs supported copper 
E. coli: Escherichia coli 
E. faecalis: Enterococcus faecalis 
ECDC: European Centre for Disease Prevention and Control  
EFSA: European Food Safety Authority  
EGCG: Epigallocatechin-3-gallate 
EPR: Enhanced permeability and retention  
EUC: eucalyptus 
FB11: Antibody for lipopolysaccharide (LPS) present in the Francisella tularensis 
FB11-mFt LPS-MSNPs: MSNPs functionalized with an antibody for Ft LPS through a derivative of the O-antigen of Ft 
LPS 
FM4-64FX: FM 4-64FX, fixable analog of FM 4-64 membrane stain 
Fn: Francisella novocida  
Ft LPS: lipopolysaccharide (LPS) present in F. tularensis (Ft) 
Ft: F. tularensis: Francisella tularensis 
G-: Gram negative bacteria 
G+: Gram positive bacteria 
G3: polycationic dendrimer, poly(propyleneimine) dendrimer of third generation 
Gel/SiO2-Gen NP coated Ti : titanium surface coated with a composite made of gelatin and “gentamicin-rich nuclei” 
silica nanoparticles 
Gen: Gentamicin 
HEK293:Human embryonic kidney 293 cells 
HKAIs: Histidine kinase autophosphorylation inhibitors 
HMSN-LP: rod shaped hollow MSNPs with large cone shaped pores 
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HOMSNs: Hollow oblate mesoporous silica nanoparticles 
IAAH: Indole-3 Acetic Acid Complex  
IBN-3: Mesocellular foam 
IBN-4 IAAH-MSNPs: Silver−Indole-3 Acetic Acid Complex based on IBN-4 silica nanoparticles 
INH: Isoniazid 
Izo: izohidrafural 
K. pneumoniae: Klebsiella pneumoniae 
Levo: Levofloxacin 
LMU-1 bth@MSNPs: bis(trimethoxysilyl)hexane (bth) coated MSNPs with non-ordered pores 
LMU-1: Disordered mesoporous structure 
LPS: Lipopolysaccharide 
lys: Lysozyme 
M. morganii: Morganella morganii 
M. smegmatis: Micobacterium smegmatis 
MBI: 1-methyl-1H-benzimidazole  
MCM-41 DAMO-MSNPs: MCM-41 type MSNPs functionalized with DAMO 
MCM-41 G3-MSNPs: MCM-41 type MSNPs functionalized with G3 
MCM-41 MBI-MSNPs: 1-methyl-1H-benzimidazole functionalized MSNPs with MCM-41 structure 
MCM-41 nHAp@MSNPs: nanohydroxyapatite/mesoporous silica nanoparticles 
MCM-41 PMMA/MSNPs: Poly(methyl methacrylate) resine containing MCM-41 MSNPs 
MCM-41 Van-MSNPs: MCM-41 type MSNPs functionalized with Vancomicin 
MCM-41 ε-pLys-MSNPs: MCM-41 type MSNPs functionalized with ε-pLys 
MCM-41: Mesoporous structure with a hexagonal pattern 
MCM-48: Mesoporous structure with a cubic pattern 
MIC: Minimun Inhibiory Concentration  
MSM: Mesoporous silica materials 
MSMAs/FSR film: Mesoporous silica microcapsules with AgNPs supported onto the interior walls incorporated onto 
the hydrophobic fluoro-silicone resin. 
MSMi: Mesoporous silica microtubes  
MSNPs: MSM in the form of nanoparticles  
MSNPs@C-dots/RB: carbon dots and Rose Bengal embedded mesoporous silica nanoparticles 
MSNPs-SB-Ni: MSNPs supported nickel 
MSR-1/MSMi: Mesoporous silica microtubes (MSMi) with MSR-1 inside 
MSR-1: Magnetosopirrillum gryphiswalense 
MXF: Moxiﬂoxacin 
Nafion@MSNPs: Nafion coated MSNPs 
nHAp@MSNPs: nanohydroxyapatite/mesoporous silica nanoparticles 
NMs: Nanomaterials 
N-MSNPs: aminated MSNPs 
NPs: Nanoparticles 
ORA: orange 
P. aeruginosa: Pseudomonas aeruginosa 
P. mirabilis: Proteus mirabilis 
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PMMA: Poly(methyl methacrylate)  
pMSN-GIC: Glass ionomer cement containing expanded-pore 
PolyB: Polymyxin B  
RB: Rose bengal 
ROS: Reactive oxygen species  
S. aureus: Staphylococcus aureus 
S. enterica: Salmonella enterica 
S. epidermidis: Staphylococcus epidermidis 
S. mutans: Streptococcus mutans 
S. oralis: Streptococcus oralis 
SB: Schiff base 
SBA-15 Ag/MSNPs: Mesoporous silica nanoparticles with hexagonal mesoporous structure and microporous 
connections decorated with silver NPs 
SBA-15 DAMO-MSN: SBA15 material functionalized with (N-(2-aminoethyl)-3-aminopropyltrimethoxysilane) 
SBA-15 PMMA/MSNPs: Poly(methyl methacrylate) resine containing SBA-15 MSNPs 
SBA-15: Mesoporous structure with a hexagonal pattern and microporous connections 
Si-Ti-Sv: Silica-titania sieves 
TC: Tetracycline 
Tre: Trehalose 
Tre-HOMSNs: Trehalose functionalized Hollow oblate mesoporous silica nanoparticles 
UL-MSNPs: MSNPs coated with a liposome bilayer and functionalized with the ubiquicidin peptide (UBI29−41) 
UV: Ultra violet 
Van: Vancomicin 
ε-pLys: ε-poly-L-lysine cationic polymer  
Author Contributions: Marina Martínez-Carmona and María Vallet-Regí performed research and analysis of 
the literature, and drafted the manuscript. Yurii K. Gun’ko revised and edited the manuscript. 
Funding: This research was funded by NAME OF FUNDER, grant number XXX 
Acknowledgments: M. Vallet-Regí acknowledges the European Research Council, ERC-2015-AdG (VERDI), 
Proposal No. 694160, and Ministerio de Economía y Competitividad (MINECO) (MAT2015-64831-R grant). M. 
Martínez-Carmona also thanks the Irish Research Council for the Postdoctoral fellowship. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Jeon, Y.S.; Chun, J.; Kim, B.S. Identification of household bacterial community and analysis of species 
shared with human microbiome. Curr. Microbiol. 2013, 67, 557–563, doi:10.1007/s00284-013-0401-y. 
2. Josephson, K.L.; Rubino, J.R.; Pepper, I.L. Characterization and quantification of bacterial pathogens and 
indicator organisms in household kitchens with and without the use of a disinfectant cleaner. J. Appl. 
Microbiol. 1997, 83, 737–750, doi:10.1046/j.1365-2672.1997.00308.x. 
3. Reynolds, K.A.; Watt, P.M.; Boone, S.A.; Gerba, C.P. Occurrence of bacteria and biochemical markers on 
public surfaces. Int. J. Environ. Health Res. 2005, 15, 225–234, doi:10.1080/09603120500115298. 
4. Bright, K.R.; Boone, S.A.; Gerba, C.P. Occurrence of bacteria and viruses on elementary classroom surfaces 
and the potential role of classroom hygiene in the spread of infectious diseases. J. Sch. Nurs. 2010, 26, 33–
41, doi:10.1177/1059840509354383. 
5. Sathya, A.; Vijayabharathi, R.; Gopalakrishnan, S. Plant growth-promoting actinobacteria: A new strategy 
for enhancing sustainable production and protection of grain legumes. 3 Biotech 2017, 7, 102, 
doi:10.1007/s13205-017-0736-3. 
Pharmaceutics 2018, 10, x 22 of 30 
 
6. Michel, V.; Martley, F.G. Streptococcus thermophilus in Cheddar cheese—Production and fate of 
galactose. J. Dairy Res. 2001, 68, 317–325, doi:10.1017/S0022029901004812. 
7. Dodds, D.R. Antibiotic resistance: A current epilogue. Biochem. Pharmacol. 2017, 134, 139–146, 
doi:10.1016/j.bcp.2016.12.005. 
8. MacGowan, A.; Macnaughton, E. Antibiotic resistance. Medicine 2017, 45, 622–628, 
doi:10.1016/j.mpmed.2017.07.006. 
9. European Food Safety Authority; European Centre for Disease Prevention and Control. The European 
Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, 
animals and food in 2016. EFSA J. 2018, 16, 5182, doi:10.2903/j.efsa.2018.5182. 
10. Kumar, A.; Alam, A.; Rani, M.; Ehtesham, N.Z.; Hasnain, S.E. Biofilms: Survival and defense strategy for 
pathogens. Int. J. Med. Microbiol. 2017, 307, 481–489, doi:10.1016/j.ijmm.2017.09.016. 
11. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. 
Antimicrob. Agents 2018, 35, 322–332, doi:10.1016/j.ijantimicag.2009.12.011. 
12. Weledji, E.P.; Weledji, E.K.; Assob, J.C.; Nsagha, D.S. Pros, cons and future of antibiotics. New Horiz. 
Transl. Med. 2017, 4, 9–14, doi:10.1016/j.nhtm.2017.08.001. 
13. Shatzkes, K.; Connell, N.D.; Kadouri, D.E. Predatory bacteria: A new therapeutic approach for a 
post-antibiotic era. Future Microbiol. 2017, 12, 469–472, doi:10.2217/fmb-2017-0021. 
14. El-Shibiny, A.; El-Sahhar, S. Bacteriophages: The possible solution to treat infections caused by pathogenic 
bacteria. Can. J. Microbiol. 2017, 63, 865–879, doi:10.1139/cjm-2017-0030. 
15. Cotter, P.D.; Ross, R.P.; Hill, C. Bacteriocins—A viable alternative to antibiotics? Nat. Rev. Microbiol. 2013, 
11, 95–105, doi:10.1038/nrmicro2937. 
16. Naderi, A.; Kasra-Kermanshahi, R.; Gharavi, S.; Imani Fooladi, A.A.; Abdollahpour Alitappeh, M.; 
Saffarian, P. Study of antagonistic effects of Lactobacillus strains as probiotics on multi drug resistant 
(MDR) bacteria isolated from urinary tract infections (UTIs). Iran. J. Basic Med. Sci. 2014, 17, 201–208. 
17. Vitetta, L.; Vitetta, G.; Hall, S. Immunological Tolerance and Function: Associations Between Intestinal 
Bacteria, Probiotics, Prebiotics, and Phages. Front. Immunol. 2018, 9, 2240, doi:10.3389/fimmu.2018.02240. 
18. Eskape, G.; Drug, C.; Potential, T. Antibiotics Currently in Global Clinical Development. 2018. Available 
online: 
https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-
development (accessed on Date, Month, Year). 
19. Zhu, X.; Radovic-Moreno, A.F.; Wu, J.; Langer, R.; Shi, J. Nanomedicine in the Management of Microbial 
Infection—Overview and Perspectives. Nano Today 2014, 9, 478–498, doi:10.1016/j.nantod.2014.06.003. 
20. Hemeg, H. Nanomaterials for alternative antibacterial therapy. Int. J. Nanomed. 2017, 12, 8211–8225, 
doi:10.2147/IJN.S132163. 
21. Yuan, P.; Ding, X.; Yang, Y.Y.; Xu, Q.-H. Metal Nanoparticles for Diagnosis and Therapy of Bacterial 
Infection. Adv. Healthc. Mater. 2018, 7, 1701392, doi:10.1002/adhm.201701392. 
22. Martínez-Carmona, M.; Gun’ko, Y.; Vallet-Regí, M. ZnO Nanostructures for Drug Delivery and 
Theranostic Applications. Nanomaterials 2018, 8, 268, doi:10.3390/nano8040268. 
23. Hancock, R.E.W.; Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic 
strategies. Nat. Biotechnol. 2006, 24, 1551–1557, doi:10.1038/nbt1267. 
24. Razei, A.; Cheraghalii, A.M.; Saadati, M.; Ramandi, M.F.; Panahi, Y. Application of nanoparticles drug 
delivery systems in the treatment of intracellular bacterial infections. Minerva Biotecnol. 2017, 29, 156–165, 
doi:10.23736/S1120-4826.17.02221-2. 
25. Wang, L.; Hu, C.; Shao, L. The antimicrobial activity of nanoparticles: Present situation and prospects for 
the future. Int. J. Nanomed. 2017, 12, 1227–1249, doi:10.2147/IJN.S121956. 
26. Eid, K.A.M.; Azzazy, H.M.E. Sustained broad-spectrum antibacterial effects of nanoliposomes loaded with 
silver nanoparticles. Nanomedicine 2014, 9, 1301–1310, doi:10.2217/nnm.13.89. 
27. Sammour, O.A.; Hassan, H.M. Enhancement of the antibacterial activity of ampicillin by liposome 
encapsulation. Drug Deliv. 1996, 3, 273–278, doi:10.3109/10717549609029460. 
28. Cheow, W.S.; Hadinoto, K. Antibiotic Polymeric Nanoparticles for Biofilm-Associated Infection Therapy. 
In Microbial Biofilms: Methods and Protocols; Donelli, G., Ed.; Springer: New York, NY, USA, 2014; pp. 227–
238, ISBN 978-1-4939-0467-9. 
29. Huang, W.; Tsui, C.P.; Tang, C.Y.; Gu, L. Effects of Compositional Tailoring on Drug Delivery Behaviours 
of Silica Xerogel/Polymer Core-shell Composite Nanoparticles. Sci. Rep. 2018, 8, 13002, 
Pharmaceutics 2018, 10, x 23 of 30 
 
doi:10.1038/s41598-018-31070-9. 
30. Vallet-Regí, M.; Manzano, M.; González-Calbet, J.M.; Okunishi, E. Evidence of drug confinement into 
silica mesoporous matrices by STEM spherical aberration corrected microscopy. Chem. Commun. 2010, 46, 
2956–2958, doi:10.1039/c000806k. 
31. ALOthman, Z. A Review: Fundamental Aspects of Silicate Mesoporous Materials. Materials 2012, 5, 2874–
2902, doi:10.3390/ma5122874. 
32. Vallet-Regi, M.; Balas, F.; Arcos, D. Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 2007, 46, 
7548–7558, doi:10.1002/anie.200604488. 
33. Hoffmann, F.; Cornelius, M.; Morell, J.; Fröba, M. Silica-Based Mesoporous Organic–Inorganic Hybrid 
Materials. Angew. Chem. Int. Ed. 2006, 45, 3216–3251, doi:10.1002/anie.200503075. 
34. Nishihara, H.; Kyotani, T. Templated Nanocarbons for Energy Storage. Adv. Mater. 2012, 24, 4473–4498, 
doi:10.1002/adma.201201715. 
35. Behrens, P.; Glaue, A.; Haggenmüller, C.; Schechner, G. Structure-directed materials syntheses: Synthesis 
field diagrams for the preparation of mesostructured silicas. Solid State Ion. 1997, 101–103, 255–260, 
doi:10.1016/S0167-2738(97)84039-8. 
36. Han, Y.; Ying, J.Y. Generalized fluorocarbon-surfactant-mediated synthesis of nanoparticles with various 
mesoporous structures. Angew. Chem. Int. Ed. 2004, 44, 288–292, doi:10.1002/anie.200460892. 
37. Lettow, J.S.; Han, Y.J.; Schmidt-Winkel, P.; Yang, P.; Zhao, D.; Stucky, G.D.; Ying, J.Y. Hexagonal to 
Mesocellular Foam Phase Transition in Polymer-Templated Mesoporous Silicas. Langmuir 2000, 16, 8291–
8295, doi:10.1021/la000660h. 
38. Du, X.; Qiao, S.Z. Dendritic Silica Particles with Center-Radial Pore Channels: Promising Platforms for 
Catalysis and Biomedical Applications. Small 2014, 11, 392–413, doi:10.1002/smll.201401201. 
39. Chen, J.-F.; Ding, H.-M.; Wang, J.-X.; Shao, L. Preparation and characterization of porous hollow silica 
nanoparticles for drug delivery application. Biomaterials 2004, 25, 723–727, 
doi:10.1016/S0142-9612(03)00566-0. 
40. Kuijk, A.; Byelov, D.V.; Petukhov, A.V.; van Blaaderen, A.; Imhof, A. Phase behavior of colloidal silica 
rods. Faraday Discuss. 2012, 159, 181, doi:10.1039/c2fd20084h. 
41. Hao, N.; Chen, X.; Jeon, S.; Yan, M. Carbohydrate-Conjugated Hollow Oblate Mesoporous Silica 
Nanoparticles as Nanoantibiotics to Target Mycobacteria. Adv. Healthc. Mater. 2015, 4, 2797–2801, 
doi:10.1002/adhm.201500491. 
42. Chen, L.; Wen, Y. The role of bacterial biofilm in persistent infections and control strategies. Int. J. Oral Sci. 
2011, 3, 66–73, doi:10.4248/IJOS11022. 
43. Hsiao, I.; Gramatke, A.M.; Joksimovic, R.; Sokolowski, M.; Gradzielski, M.; Haase, A. Size and Cell Type 
Dependent Uptake of Silica Nanoparticles. J. Nanomed. Nanotechnol. 2014, 5, 248, doi:10.4172/2157–
7439.1000248. 
44. Wehling, J.; Volkmann, E.; Grieb, T.; Rosenauer, A.; Maas, M.; Treccani, L.; Rezwan, K. A critical study: 
Assessment of the effect of silica particles from 15 to 500 nm on bacterial viability. Environ. Pollut. 2013, 
176, 292–299, doi:10.1016/j.envpol.2013.02.001. 
45. Mathelié-Guinlet, M.; Béven, L.; Moroté, F.; Moynet, D.; Grauby-Heywang, C.; Gammoudi, I.; Delville, M.; 
Cohen-Bouhacina, T. Probing the threshold of membrane damage and cytotoxicity effects induced by 
silica nanoparticles in Escherichia coli bacteria. Adv. Colloid Interface Sci. 2017, 245, 81–91, 
doi:10.1016/j.cis.2017.04.012. 
46. Slomberg, D.L.; Lu, Y.; Broadnax, A.D.; Hunter, R.A.; Carpenter, A.W.; Schoenfisch, M.H. Role of Size and 
Shape on Biofilm Eradication for Nitric Oxide-Releasing Silica Nanoparticles. ACS Appl. Mater. Interfaces 
2013, 5, 9322–9329, doi:10.1021/am402618w. 
47. Vallet-Regí, M. Ordered mesoporous materials in the context of drug delivery systems and bone tissue 
engineering. Chemistry 2006, 12, 5934–5943, doi:10.1002/chem.200600226. 
48. Vallet-Regí, M.; Salinas, A.; Baeza, A.; Manzano, M. Smart nanomaterials and nanostructures for 
diagnostic and therapy. Chem. Eng. J. 2018, 340, 1–196, doi:10.1016/j.cej.2018.02.069. 
49. Chen, L.; Zhang, J. Bioconjugated Magnetic Nanoparticles for Rapid Capture of Gram-positive Bacteria. J. 
Biosens. Bioelectron. 2012, 1, doi:10.4172/2155–6210.S11-005. 
50. Zhao, X.; Hilliard, L.R.; Mechery, S.J.; Wang, Y.; Bagwe, R.P.; Jin, S.; Tan, W. A rapid bioassay for single 
bacterial cell quantitation using bioconjugated nanoparticles. Proc. Natl. Acad. Sci. USA 2004, 101, 15027–
15032, doi:10.1073/pnas.0404806101. 
Pharmaceutics 2018, 10, x 24 of 30 
 
51. Zhu, C.; Zhao, G.; Dou, W. Core-shell red silica nanoparticles based immunochromatographic assay for 
detection of Escherichia coli O157:H7. Anal. Chim. Acta 2018, 1038, 97–104, doi:10.1016/j.aca.2018.07.003. 
52. Wang, R.; Xu, Y.; Jiang, Y.; Chuan, N.; Su, X.; Ji, J. Sensitive quantification and visual detection of bacteria 
using CdSe/ZnS@SiO2 nanoparticles as fluorescent probes. Anal. Methods 2014, 6, 6802–6808, 
doi:10.1039/C4AY01257G. 
53. Gisbert-Garzarán, M.; Manzano, M.; Vallet-Regí, M. Self-immolative chemistry in nanomedicine. Chem. 
Eng. J. 2018, 340, 24–31, doi:10.1016/j.cej.2017.12.098. 
54. Paris, J.L.; Mannaris, C.; Cabañas, M.V.; Carlisle, R.; Manzano, M.; Vallet-Regí, M.; Coussios, C.C. 
Ultrasound-mediated cavitation-enhanced extravasation of mesoporous silica nanoparticles for 
controlled-release drug delivery. Chem. Eng. J. 2018, 340, 2–8, doi:10.1016/j.cej.2017.12.051. 
55. Izquierdo-Barba, I.; Colilla, M.; Vallet-Regí, M. Zwitterionic ceramics for biomedical applications. Acta 
Biomater. 2016, 40, 201–211, doi:10.1016/j.actbio.2016.02.027. 
56. Yang, S.; Han, X.; Yang, Y.; Qiao, H.; Yu, Z.; Liu, Y.; Wang, J.; Tang, T. Bacteria-Targeting Nanoparticles 
with Microenvironment-Responsive Antibiotic Release to Eliminate Intracellular Staphylococcus aureus 
and Associated Infection. ACS Appl. Mater. Interfaces 2018, 10, 14299–14311, doi:10.1021/acsami.7b15678. 
57. Yang, Y.; Jambhrunkar, M.; Abbaraju, P.L.; Yu, M.; Zhang, M.; Yu, C. Understanding the Effect of Surface 
Chemistry of Mesoporous Silica Nanorods on Their Vaccine Adjuvant Potency. Adv. Healthc. Mater. 2017, 
6, 1–12, doi:10.1002/adhm.201700466. 
58. Navarro-Tovar, G.; Palestino, G.; Rosales-Mendoza, S. An overview on the role of silica-based materials in 
vaccine development. Expert Rev. Vaccines 2016, 15, 1449–1462, doi:10.1080/14760584.2016.1188009. 
59. Vallet-Regí, M. Nanostructured mesoporous silica matrices in nanomedicine. J. Intern. Med. 2010, 267, 22–
43, doi:10.1111/j.1365-2796.2009.02190.x. 
60. Wang, Y.; Zhao, Q.; Han, N.; Bai, L.; Li, J.; Liu, J.; Che, E.; Hu, L.; Zhang, Q.; Jiang, T.; et al. Mesoporous 
silica nanoparticles in drug delivery and biomedical applications. Nanomed. Nanotechnol. Biol. Med. 2015, 
11, 313–327, doi:10.1016/j.nano.2014.09.014. 
61. Baeza, A.; Colilla, M.; Vallet-Regí, M. Advances in mesoporous silica nanoparticles for targeted 
stimuli-responsive drug delivery. Expert Opin. Drug Deliv. 2015, 12, 319–337, 
doi:10.1517/17425247.2014.953051. 
62. Vallet-Regí, M.; Rámila, A.; del Real, R.P.; Pérez-Pariente, J. A New Property of MCM-41: Drug Delivery 
System. Chem. Mater. 2001, 13, 308–311, doi:10.1021/cm0011559. 
63. Sevimli, F.; Yılmaz, A. Surface functionalization of SBA-15 particles for amoxicillin delivery. Microporous 
Mesoporous Mater. 2012, 158, 281–291, doi:10.1016/j.micromeso.2012.02.037. 
64. Hashemikia, S.; Hemmatinejad, N.; Ahmadi, E.; Montazer, M. Optimization of tetracycline hydrochloride 
adsorption on amino modified SBA-15 using response surface methodology. J. Colloid Interface Sci. 2015, 
443, 105–114, doi:10.1016/j.jcis.2014.11.020. 
65. Vallet-Regí, M.; Doadrio, J.C.; Doadrio, A.L.; Izquierdo-Barba, I.; Pérez Pariente, J. Hexagonal ordered 
mesoporous material as a matrix for the controlled release of amoxicillin. Solid State Ion. 2004, 172, 435–439, 
doi:10.1016/j.ssi.2004.04.036. 
66. Molina-Manso, D.; Manzano, M.; Doadrio, J.C.; Del Prado, G.; Ortiz-Pérez, A.; Vallet-Regí, M.; 
Gómez-Barrena, E.; Esteban, J. Usefulness of SBA-15 mesoporous ceramics as a delivery system for 
vancomycin, rifampicin and linezolid: A preliminary report. Int. J. Antimicrob. Agents 2012, 40, 252–256, 
doi:10.1016/j.ijantimicag.2012.05.013. 
67. Koneru, B.; Shi, Y.; Wang, Y.; Chavala, S.; Miller, M.; Holbert, B.; Conson, M.; Ni, A.; Di Pasqua, A. 
Tetracycline-Containing MCM-41 Mesoporous Silica Nanoparticles for the Treatment of Escherichia coli. 
Molecules 2015, 20, 19690–19698, doi:10.3390/molecules201119650. 
68. Lu, M.; Wang, Q.; Chang, Z.; Wang, Z.; Zheng, X.; Shao, D.; Dong, W.; Zhou, Y. Synergistic bactericidal 
activity of chlorhexidine-loaded, silver-decorated mesoporous silica nanoparticles. Int. J. Nanomed. 2017, 
12, 3577–3589, doi:10.2147/IJN.S133846. 
69. Gounani, Z.; Asadollahi, M.A.; Meyer, R.L.; Arpanaei, A. Loading of polymyxin B onto anionic 
mesoporous silica nanoparticles retains antibacterial activity and enhances biocompatibility. Int. J. Pharm. 
2018, 537, 148–161, doi:10.1016/j.ijpharm.2017.12.039. 
70. Balaure, P.C.; Boarca, B.; Popescu, R.C.; Savu, D.; Trusca, R.; Vasile, B.Ș.; Grumezescu, A.M.; Holban, A.M.; 
Bolocan, A.; Andronescu, E. Bioactive mesoporous silica nanostructures with anti-microbial and 
anti-biofilm properties. Int. J. Pharm. 2017, 531, 35–46, doi:10.1016/j.ijpharm.2017.08.062. 
Pharmaceutics 2018, 10, x 25 of 30 
 
71. Ganguly, A.; Ahmad, T.; Ganguli, A.K. Silica mesostructures: Control of pore size and surface area using a 
surfactant-templated hydrothermal process. Langmuir 2010, 26, 14901–14908, doi:10.1021/la102510c. 
72. Wang, Y.; Nor, Y.A.; Song, H.; Yang, Y.; Xu, C.; Yu, M.; Yu, C. Small-sized and large-pore dendritic 
mesoporous silica nanoparticles enhance antimicrobial enzyme delivery. J. Mater. Chem. B 2016, 4, 2646–
2653, doi:10.1039/C6TB00053C. 
73. Seleem, M.N.; Munusamy, P.; Ranjan, A.; Alqublan, H.; Pickrell, G.; Sriranganathan, N. Silica-antibiotic 
hybrid nanoparticles for targeting intracellular pathogens. Antimicrob. Agents Chemother. 2009, 53, 4270–
4274, doi:10.1128/AAC.00815-09. 
74. Yasuyuki, M.; Kunihiro, K.; Kurissery, S.; Kanavillil, N.; Sato, Y.; Kikuchi, Y. Antibacterial properties of 
nine pure metals: A laboratory study using Staphylococcus aureus and Escherichia coli. Biofouling 2010, 26, 
851–858, doi:10.1080/08927014.2010.527000. 
75. Sánchez-Salcedo, S.; Shruti, S.; Salinas, A.J.; Malavasi, G.; Menabue, L.; Vallet-Regí, M. In vitro 
antibacterial capacity and cytocompatibility of SiO2–CaO–P2O5 meso-macroporous glass scaffolds 
enriched with ZnO. J. Mater. Chem. B 2014, 2, 4836–4847, doi:10.1039/C4TB00403E. 
76. Liong, M.; France, B.; Bradley, K.A.; Zink, J.I. Antimicrobial Activity of Silver Nanocrystals Encapsulated 
in Mesoporous Silica Nanoparticles. Adv. Mater. 2009, 21, 1684–1689, doi:10.1002/adma.200802646. 
77. Carmona, D.; Lalueza, P.; Balas, F.; Arruebo, M.; Santamaría, J. Mesoporous silica loaded with peracetic 
acid and silver nanoparticles as a dual-effect, highly efficient bactericidal agent. Microporous Mesoporous 
Mater. 2012, 161, 84–90, doi:10.1016/j.micromeso.2012.05.012. 
78. Tahmasbi, L.; Sedaghat, T.; Motamedi, H.; Kooti, M. Mesoporous silica nanoparticles supported copper(II) 
and nickel(II) Schiff base complexes: Synthesis, characterization, antibacterial activity and enzyme 
immobilization. J. Solid State Chem. 2018, 258, 517–525, doi:10.1016/j.jssc.2017.11.015. 
79. Al Tameemi, M.B.M.; Stan, R.; Prisacari, V.; Voicu, G.; Popa, M.; Chifiriuc, M.C.; Ott, C.; Marton, G.; 
Meghea, A. Antimicrobial performance of nanostructured silica–titania sieves loaded with izohidrafural 
against microbial strains isolated from urinary tract infections. C. R. Chim. 2017, 20, 475–483, 
doi:10.1016/j.crci.2016.09.007. 
80. Liu, Y.; Liu, X.; Xiao, Y.; Chen, F.; Xiao, F. A multifunctional nanoplatform based on mesoporous silica 
nanoparticles for imaging-guided chemo/photodynamic synergetic therapy. RSC Adv. 2017, 7, 31133–
31141, doi:10.1039/c7ra04549b. 
81. Sun, T.; Zhang, Y.S.; Pang, B.; Hyun, D.C.; Yang, M.; Xia, Y. Engineered Nanoparticles for Drug Delivery 
in Cancer Therapy. Angew. Chem. Int. Ed. 2014, 53, 12320–12364, doi:10.1002/anie.201403036. 
82. Maeda, H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with 
emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn Acad. Ser. B 2012, 88, 53–71, 
doi:10.2183/pjab.88.53. 
83. Azzopardi, E.A.; Ferguson, E.L.; Thomas, D.W. The enhanced permeability retention effect: A new 
paradigm for drug targeting in infection. J. Antimicrob. Chemother. 2013, 68, 257–274, 
doi:10.1093/jac/dks379. 
84. Aparna, V.; Shiva, M.; Biswas, R.; Jayakumar, R. Biological macromolecules based targeted nanodrug 
delivery systems for the treatment of intracellular infections. Int. J. Biol. Macromol. 2018, 110, 2–6, 
doi:10.1016/j.ijbiomac.2018.01.030. 
85. Edgar, R.; McKinstry, M.; Hwang, J.; Oppenheim, A.B.; Fekete, R.A.; Giulian, G.; Merril, C.; Nagashima, 
K.; Adhya, S. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot 
nanocomplexes. Proc. Natl. Acad. Sci. 2006, 103, 4841–4845, doi:10.1073/pnas.0601211103. 
86. Tang, E.N.; Nair, A.; Baker, D.W.; Hu, W.; Zhou, J. In Vivo Imaging of Infection Using a Bacteria-Targeting 
Optical Nanoprobe. J. Biomed. Nanotechnol. 2014, 10, 856–863. 
87. Bandyopadhyay, A.; McCarthy, K.A.; Kelly, M.A.; Gao, J. Targeting Bacteria via Iminoboronate Chemistry 
of Amine-Presenting Lipids. Nat. Commun. 2015, 6, 6561, doi:10.1038/ncomms7561. 
88. Lu, H.D.; Yang, S.S.; Wilson, B.K.; McManus, S.A.; Chen, C.V.H.-H.; Prud’homme, R.K. Nanoparticle 
targeting of Gram-positive and Gram-negative bacteria for magnetic-based separations of bacterial 
pathogens. Appl. Nanosci. 2017, 7, 83–93, doi:10.1007/s13204-017-0548-0. 
89. Epand, R.M.; Walker, C.; Epand, R.F.; Magarvey, N.A. Molecular mechanisms of membrane targeting 
antibiotics. Biochim. Biophys. Acta Biomembr. 2016, 1858, 980–987, doi:10.1016/j.bbamem.2015.10.018. 
90. Aleksandar, F.; Lu, T.K.; Vlad, A.; Yoon, C.J.; Langer, R.; Omid, C.; Link, C. Surface Charge-Switching 
Polymeric Nanoparticles for Bacterial Cell Wall-Targeted Delivery of Antibiotics. ACS Nano 2012, 6, 4279–
Pharmaceutics 2018, 10, x 26 of 30 
 
4287, doi:10.1021/nn3008383.Surface. 
91. González, B.; Díez, J.; Pedraza, D.; Guembe, M.; Izquierdo-barba, I.; Vallet-regí, M. Mesoporous silica 
nanoparticles decorated with polycationic dendrimers for infection treatment. Acta Biomater. 2018, 68, 261–
271, doi:10.1016/j.actbio.2017.12.041. 
92. Ruiz-Rico, M.; Pérez-Esteve, É.; de la Torre, C.; Jiménez-Belenguer, A.I.; Quiles, A.; Marcos, M.D.; 
Martínez-Máñez, R.; Barat, J.M. Improving the Antimicrobial Power of Low-Effective Antimicrobial 
Molecules Through Nanotechnology. J. Food Sci. 2018, 83, 2140–2147, doi:10.1111/1750–3841.14211. 
93. Velikova, N.; Mas, N.; Miguel-romero, L.; Polo, L.; Stolte, E.; Zaccaria, E.; Cao, R.; Taverne, N.; Murguía, 
J.R.; Martinez-manez, R.; et al. Broadening the antibacterial spectrum of histidine kinase 
autophosphorylation inhibitors via the use of ε-poly-L-lysine capped mesoporous silica-based 
nanoparticles. Nanomed. Nanotechnol. Biol. Med. 2017, 13, 569–581, doi:10.1016/j.nano.2016.09.011. 
94. Gustafson, H.H.; Holt-Casper, D.; Grainger, D.W.; Ghandehari, H. Nanoparticle Uptake: The Phagocyte 
Problem. Nano Today 2015, 10, 487–510, doi:10.1016/j.nantod.2015.06.006. 
95. Qi, G.; Li, L.; Yu, F.; Wang, H. Vancomycin-modified mesoporous silica nanoparticles for selective 
recognition and killing of pathogenic gram-positive bacteria over macrophage-like cells. ACS Appl. Mater. 
Interfaces 2013, 5, 10874–10881, doi:10.1021/am403940d. 
96. Jayawardana, K.W.; Jayawardena, H.S.N.; Wijesundera, S.A.; De Zoysa, T.; Sundhoro, M.; Yan, M. 
Selective targeting of Mycobacterium smegmatis with trehalose-functionalized nanoparticles. Chem. 
Commun. 2015, 51, 12028–12031, doi:10.1039/c5cc04251h. 
97. Takayama, K.; Davidson, L.A. Antimycobacterial drugs that inhibit mycolic acid synthesis. Trends Biochem. 
Sci. 1979, 4, 280–282, doi:10.1016/0968-0004(79)90301-3. 
98. Thanna, S.; Sucheck, S.J. Targeting the trehalose utilization pathways of Mycobacterium tuberculosis. 
Medchemcomm 2016, 7, 69–85, doi:10.1039/C5MD00376H. 
99. Martínez-Carmona, M.; Colilla, M.; Vallet-Regí, M. Smart Mesoporous Nanomaterials for Antitumor 
Therapy. Nanomaterials 2015, 5, 1906–1937. 
100. Zhu, J.; Niu, Y.; Li, Y.; Gong, Y.; Shi, H.; Huo, Q.; Liu, Y.; Xu, Q. Stimuli-responsive delivery vehicles based 
on mesoporous silica nanoparticles: Recent advances and challenges. J. Mater. Chem. B 2017, 5, 1339–1352, 
doi:10.1039/C6TB03066A. 
101. Vallet-Regí, M.; Colilla, M.; Izquierdo-Barba, I.; Manzano, M. Mesoporous Silica Nanoparticles for Drug 
Delivery: Current Insights. Molecules 2017, 23, 47, doi:10.3390/molecules23010047. 
102. Polo, L.; Gómez-Cerezo, N.; Aznar, E.; Vivancos, J.-L.; Sancenón, F.; Arcos, D.; Vallet-Regí, M.; 
Martínez-Máñez, R. Molecular gates in mesoporous bioactive glasses for the treatment of bone tumors and 
infection. Acta Biomater. 2017, 50, 114–126, doi:10.1016/j.actbio.2016.12.025. 
103. Handke, L.D.; Rogers, K.L.; Olson, M.E.; Somerville, G.A.; Jerrells, T.J.; Rupp, M.E.; Dunman, P.M.; Fey, 
P.D. Staphylococcus epidermidis saeR Is an Effector of Anaerobic Growth and a Mediator of Acute 
Inflammation. Infect. Immun. 2008, 76, 141–152, doi:10.1128/IAI.00556-07. 
104. Fuchs, S.; Pané-Farré, J.; Kohler, C.; Hecker, M.; Engelmann, S. Anaerobic Gene Expression in 
Staphylococcus aureus. J. Bacteriol. 2007, 189, 4275–4289, doi:10.1128/JB.00081-07. 
105. Tamanna, T.; Bulitta, J.B.; Yu, A. Controlling antibiotic release from mesoporous silica nano drug carriers 
via self-assembled polyelectrolyte coating. J. Mater. Sci. Mater. Med. 2015, 26, 117, 
doi:10.1007/s10856-015-5444-0. 
106. Kuthati, Y.; Kankala, R.K.; Lin, S.; Weng, C.; Lee, C. pH-Triggered Controllable Release of Silver–Indole-3 
Acetic Acid Complexes from Mesoporous Silica Nanoparticles (IBN-4) for Effectively Killing Malignant 
Bacteria. Mol. Pharm. 2015, 12, 2289–2304, doi:10.1021/mp500836w. 
107. Jung, W.K.; Koo, H.C.; Kim, K.W.; Shin, S.; Kim, S.H.; Park, Y.H. Antibacterial Activity and Mechanism of 
Action of the Silver Ion in Staphylococcus aureus and Escherichia coli . Appl. Environ. Microbiol. 2008, 74, 
2171–2178, doi:10.1128/AEM.02001-07. 
108. Dibrov, P.; Dzioba, J.; Gosink, K.K.; Häse, C.C. Chemiosmotic Mechanism of Antimicrobial Activity of 
Ag(+) in Vibrio cholerae. Antimicrob. Agents Chemother. 2002, 46, 2668–2670, 
doi:10.1128/AAC.46.8.2668-2670.2002. 
109. Park, H.-J.; Kim, J.Y.; Kim, J.; Lee, J.-H.; Hahn, J.-S.; Gu, M.B.; Yoon, J. Silver-ion-mediated reactive oxygen 
species generation affecting bactericidal activity. Water Res. 2009, 43, 1027–1032, 
doi:10.1016/j.watres.2008.12.002. 
110. Li, Z.; Clemens, D.L.; Lee, B.Y.; Dillon, B.J.; Horwitz, M.A.; Zink, J.I. Mesoporous Silica Nanoparticles with 
Pharmaceutics 2018, 10, x 27 of 30 
 
pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic 
Tularemia. ACS Nano 2015, 9, 10778–10789, doi:10.1021/acsnano.5b04306. 
111. Ruehle, B.; Clemens, D.L.; Lee, B.-Y.; Horwitz, M.A.; Zink, J.I. A Pathogen-Specific Cargo Delivery 
Platform Based on Mesoporous Silica Nanoparticles. J. Am. Chem. Soc. 2017, 139, 6663–6668, 
doi:10.1021/jacs.7b01278. 
112. Donlan, R.M. Biofilms: Microbial Life on Surfaces. Emerg. Infect. Dis. 2002, 8, 881–890, 
doi:10.3201/eid0809.020063. 
113. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial Biofilms: A Common Cause of Persistent 
Infections. Science 1999, 284, 1318–1322, doi:10.1126/science.284.5418.1318. 
114. Tuson, H.H.; Weibel, D.B. Bacteria-surface interactions. Soft Matter 2013, 9, 4368–4380, 
doi:10.1039/c3sm27705d. 
115. Lappin-Scott, H.M.; Bass, C. Biofilm formation: Attachment, growth, and detachment of microbes from 
surfaces. Am. J. Infect. Control 2001, 29, 250–251, doi:10.1067/mic.2001.115674. 
116. Pabst, B.; Pitts, B.; Lauchnor, E.; Stewart, P.S. Gel-Entrapped Staphylococcus aureus Bacteria as Models of 
Biofilm Infection Exhibit Growth in Dense Aggregates, Oxygen Limitation, Antibiotic Tolerance, and 
Heterogeneous Gene Expression. Antimicrob. Agents Chemother. 2016, 60, 6294–6301, 
doi:10.1128/AAC.01336-16. 
117. Spear, M. The Biofilm Challenge: Breaking Down the Walls. Plast. Surg. Nurs. 2011, 31, 117–120, 
doi:10.1097/PSN.0b013e31822d1110. 
118. Biofilm the challenge. J. Wound Care 2014, 23, 519–519, doi:10.12968/jowc.2014.23.11.519. 
119. Alibert, S.; Diarra, J.N.; Hernandez, J.; Stutzmann, A.; Fouad, M.; Boyer, G.; Pagès, J.-M. Multidrug efflux 
pumps and their role in antibiotic and antiseptic resistance: A pharmacodynamic perspective. Expert Opin. 
Drug Metab. Toxicol. 2017, 13, 301–309, doi:10.1080/17425255.2017.1251581. 
120. Nicoloff, H.; Andersson, D.I. Indirect resistance to several classes of antibiotics in cocultures with resistant 
bacteria expressing antibiotic-modifying or -degrading enzymes. J. Antimicrob. Chemother. 2016, 71, 100–
110, doi:10.1093/jac/dkv312. 
121. Mooney, J.A.; Pridgen, E.M.; Manasherob, R.; Suh, G.; Blackwell, H.E.; Barron, A.E.; Bollyky, P.L.; 
Goodman, S.B.; Amanatullah, D.F. Periprosthetic bacterial biofilm and quorum sensing. J. Orthop. Res. 
2018, 36, 2331–2339, doi:10.1002/jor.24019. 
122. Sønderholm, M.; Bjarnsholt, T.; Alhede, M.; Kolpen, M.; Jensen, P.; Kühl, M.; Kragh, K. The Consequences 
of Being in an Infectious Biofilm: Microenvironmental Conditions Governing Antibiotic Tolerance. Int. J. 
Mol. Sci. 2017, 18, 2688, doi:10.3390/ijms18122688. 
123. Wolcott, R.; Dowd, S. The Role of Biofilms: Are We Hitting the Right Target? Plast. Reconstr. Surg. 2011, 
127, 28S–35S, doi:10.1097/PRS.0b013e3181fca244. 
124. Delcaru, C.; Alexandru, I.; Podgoreanu, P.; Grosu, M.; Stavropoulos, E.; Chifiriuc, M.C.; Lazar, V. 
Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating 
strategies. Pathogens 2016, 5, 65, doi:10.3390/pathogens5040065. 
125. Soto, S.M. Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches. Adv. Biol. 
2014, 2014, 543974, doi:10.1155/2014/543974. 
126. Elgharably, H.; Hussain, S.T.; Shrestha, N.K.; Blackstone, E.H.; Pettersson, G.B. Current Hypotheses in 
Cardiac Surgery: Biofilm in Infective Endocarditis. Semin. Thorac. Cardiovasc. Surg. 2016, 28, 56–59, 
doi:10.1053/j.semtcvs.2015.12.005. 
127. Boisvert, A.-A.; Cheng, M.P.; Sheppard, D.C.; Nguyen, D. Microbial Biofilms in Pulmonary and Critical 
Care Diseases. Ann. Am. Thorac. Soc. 2016, 13, 1615–1623, doi:10.1513/AnnalsATS.201603-194FR. 
128. Akyıldız, İ.; Take, G.; Uygur, K.; Kızıl, Y.; Aydil, U. Bacterial Biofilm Formation in the Middle-Ear Mucosa 
of Chronic Otitis Media Patients. Indian J. Otolaryngol. Head Neck Surg. 2013, 65, 557–561, 
doi:10.1007/s12070-012-0513-x. 
129. Tawfik, S.A.; Ibrahim, A.A.; Talaat, I.M.; El-Alkamy, S.S.; Youssef, A. Role of bacterial biofilm in 
development of middle ear effusion. Eur. Arch. Otorhinolaryngol. 2016, 273, 4003–4009, 
doi:10.1007/s00405-016-4094-2. 
130. Trautner, B.W.; Darouiche, R.O. Catheter-Associated Infections: Pathogenesis Affects Prevention. Arch. 
Intern. Med. 2004, 164, 842–850, doi:10.1001/archinte.164.8.842. 
131. Dhir, S. Biofilm and dental implant: The microbial link. J. Indian Soc. Periodontol. 2013, 17, 5, 
doi:10.4103/0972-124X.107466. 
Pharmaceutics 2018, 10, x 28 of 30 
 
132. Santos, A.P.A.; Watanabe, E.; Andrade, D. de Biofilme em marca-passo artificial: Ficção ou realidade? Arq. 
Bras. Cardiol. 2011, 97, e113–e120, doi:10.1590/S0066-782X2011001400018. 
133. Gbejuade, H.O.; Lovering, A.M.; Webb, J.C. The role of microbial biofilms in prosthetic joint infections: A 
review. Acta Orthop. 2015, 86, 147–158, doi:10.3109/17453674.2014.966290. 
134. Arciola, C.R.; Campoccia, D.; Ehrlich, G.D.; Montanaro, L. Chapter 2: Biofilm-Based Implant Infections in 
Orthopaedics. In Biofilm-Based Healthcare-Associated Infections: Volume I.; Donelli, G., Ed.; Springer 
International Publishing: Basel, Switzerland, 2015; pp. 29–46, ISBN 978-3-319-11037-0. 
135. Voo, Z.X.; Khan, M.; Xu, Q.; Narayanan, K.; Ng, B.W.J.; Bte Ahmad, R.; Hedrick, J.L.; Yang, Y.Y. 
Antimicrobial coatings against biofilm formation: The unexpected balance between antifouling and 
bactericidal behavior. Polym. Chem. 2016, 7, 656–668, doi:10.1039/C5PY01718A. 
136. Simchi, A.; Tamjid, E.; Pishbin, F.; Boccaccini, A.R. Recent progress in inorganic and composite coatings 
with bactericidal capability for orthopaedic applications. Nanomedicine 2011, 7, 22–39, 
doi:10.1016/j.nano.2010.10.005. 
137. Campoccia, D.; Montanaro, L.; Arciola, C.R. A review of the clinical implications of anti-infective 
biomaterials and infection-resistant surfaces. Biomaterials 2013, 34, 8018–8029, 
doi:10.1016/j.biomaterials.2013.07.048. 
138. Swartjes, J.J.T.M.; Sharma, P.K.; Kooten, T.G.; Mei, H.C.; Mahmoudi, M.; Busscher, H.J.; Rochford, E.T.J. 
Current Developments in Antimicrobial Surface Coatings for Biomedical Applications. Curr. Med. Chem. 
2015, 22, 2116–2129, doi:10.2174/0929867321666140916121355. 
139. Graham, M.V.; Mosier, A.P.; Kiehl, T.R.; Kaloyeros, A.E.; Cady, N.C. Development of antifouling surfaces 
to reduce bacterial attachment. Soft Matter 2013, 9, 6235–6244, doi:10.1039/c3sm50584g. 
140. Izquierdo-Barba, I.; Sánchez-Salcedo, S.; Colilla, M.; Feito, M.J.; Ramírez-Santillán, C.; Portolés, M.T.; 
Vallet-Regí, M. Inhibition of bacterial adhesion on biocompatible zwitterionic SBA-15 mesoporous 
materials. Acta Biomater. 2011, 7, 2977–2985, doi:10.1016/j.actbio.2011.03.005. 
141. Martínez-Carmona, M.; Lozano, D.; Baeza, A.; Colilla, M.; Vallet-Regí, M. A novel visible light responsive 
nanosystem for cancer treatment. Nanoscale 2017, 9, 15967–15973. doi:10.1039/c7nr05050j. 
142. Francolini, I.; Vuotto, C.; Piozzi, A.; Donelli, G. Antifouling and antimicrobial biomaterials: An overview. 
APMIS 2017, 125, 392–417, doi:10.1111/apm.12675. 
143. Colilla, M.; Martínez-Carmona, M.; Sánchez-Salcedo, S.; Ruiz-Gonzales, L.; Gonzalez-Calbet, J.M.; 
Vallet-Regi, M. A Novel Zwitterionic Bioceramic with Dual Antibacterial Capability. J. Mater. Chem. B 
2014, 2, 5639–5651, doi:10.1039/c4tb00690a. 
144. Aguilar-Colomer, A.; Doadrio, J.C.; Pérez-Jorge, C.; Manzano, M.; Vallet-Regí, M.; Esteban, J. Antibacterial 
effect of antibiotic-loaded SBA-15 on biofilm formation by Staphylococcus aureus and Staphylococcus 
epidermidis. J. Antibiot. 2017, 70, 259–263, doi:10.1038/ja.2016.154. 
145. Díez-Martínez, R.; García-Fernández, E.; Manzano, M.; Martínez, Á.; Domenech, M.; Vallet-Regí, M.; 
García, P. Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections. Sci. 
Rep. 2016, 6, 19525, doi:10.1038/srep19525. 
146. Cicuéndez, M.; Doadrio, J.C.; Hernández, A.; Portolés, M.T.; Izquierdo-Barba, I.; Vallet-Regí, M. 
Multifunctional pH sensitive 3D scaffolds for treatment and prevention of bone infection. Acta Biomater. 
2018, 65, 450–461, doi:10.1016/j.actbio.2017.11.009. 
147. García-Alvarez, R.; Izquierdo-Barba, I.; Vallet-Regí, M. 3D scaffold with effective multidrug sequential 
release against bacteria biofilm. Acta Biomater. 2017, 49, 113–126, doi:10.1016/j.actbio.2016.11.028. 
148. Voicu, G.; Elena, A.; Andronescu, E.; Grumezescu, V.; Maria, A.; Stefan, B.; Vasile, A.; Mihai, A.; Socol, G.; 
Mogos, G.D.; et al. Mesoporous silica coatings for cephalosporin active release at the bone-implant 
interface. Appl. Surf. Sci. 2016, 374, 165–171, doi:10.1016/j.apsusc.2015.10.183. 
149. Ehlert, N.; Badar, M.; Christel, A.; Lohmeier, J.; Luessenhop, T.; Stieve, M.; Lenarz, T.; Mueller, P.; Behrens, 
P. Mesoporous silica coatings for controlled release of the antibiotic ciprofloxacin from implants. J. Mater. 
Chem. 2011, 752–760, doi:10.1039/c0jm01487g. 
150. Tamanna, T.; Landersdorfer, C.B.; Ng, H.J.; Bulitta, J.B.; Wood, P.; Yu, A. Prolonged and continuous 
antibacterial and anti-biofilm activities of thin films embedded with gentamicin-loaded mesoporous silica 
nanoparticles. Appl. Nanosci. 2018, 8, 1471–1482, doi:10.1007/s13204-018-0807-8. 
151. Wang, J.; Wu, G.; Liu, X.; Sun, G.; Li, D.; Wei, H. A decomposable silica-based antibacterial coating for 
percutaneous titanium implant. Int. J. Nanomed. 2017, 12, 371–379, doi:10.2147/IJN.S123622. 
152. Massa, M.A.; Covarrubias, C.; Bittner, M.; Fuentevilla, I.A.; Capetillo, P.; Von Marttens, A.; Carvajal, J.C. 
Pharmaceutics 2018, 10, x 29 of 30 
 
Synthesis of new antibacterial composite coating for titanium based on highly ordered nanoporous silica 
and silver nanoparticles. Mater. Sci. Eng. C 2014, 45, 146–153, doi:10.1016/j.msec.2014.08.057. 
153. Wang, W.; Liao, S.; Zhu, Y.; Liu, M.; Zhao, Q.; Fu, Y. Recent applications of nanomaterials in 
prosthodontics. J. Nanomater. 2015, 2015, 408643, doi:10.1155/2015/408643. 
154. Shen, S.-C.; Ng, W.K.; Shi, Z.; Chia, L.; Neoh, K.G.; Tan, R.B.H. Mesoporous silica 
nanoparticle-functionalized poly(methyl methacrylate)-based bone cement for effective antibiotics 
delivery. J. Mater. Sci. Mater. Med. 2011, 22, 2283, doi:10.1007/s10856-011-4397-1. 
155. Lee, J.H.; El-Fiqi, A.; Jo, J.K.; Kim, D.A.; Kim, S.C.; Jun, S.K.; Kim, H.W.; Lee, H.H. Development of 
long-term antimicrobial poly(methyl methacrylate) by incorporating mesoporous silica nanocarriers. Dent. 
Mater. 2016, 32, 1564–1574, doi:10.1016/j.dental.2016.09.001. 
156. Yu, J.; Yang, H.; Li, K.; Ren, H.; Lei, J.; Huang, C. Development of Epigallocatechin-3-gallate-Encapsulated 
Nanohydroxyapatite/Mesoporous Silica for Therapeutic Management of Dentin Surface. ACS Appl. Mater. 
Interfaces 2017, 9, 25796–25807, doi:10.1021/acsami.7b06597. 
157. Yan, H.; Yang, H.; Li, K.; Yu, J.; Huang, C. Effects of Chlorhexidine-Encapsulated Mesoporous Silica 
Nanoparticles on the Anti-Biofilm and Mechanical Properties of Glass Ionomer Cement. Molecules 2017, 
22, 1225, doi:10.3390/molecules22071225. 
158. Banerjee, I.; Pangule, R.C.; Kane, R.S. Antifouling Coatings: Recent Developments in the Design of 
Surfaces That Prevent Fouling by Proteins, Bacteria, and Marine Organisms. Adv. Mater. 2010, 23, 690–718, 
doi:10.1002/adma.201001215. 
159. Zheng, J.; Li, L.; Tsao, H.-K.; Sheng, Y.-J.; Chen, S.; Jiang, S. Strong repulsive forces between protein and 
oligo (ethylene glycol) self-assembled monolayers: A molecular simulation study. Biophys. J. 2005, 89, 158–
166, doi:10.1529/biophysj.105.059428. 
160. Li, M.; Neoh, K.G.; Kang, E.T.; Lau, T.; Chiong, E. Surface modification of silicone with covalently 
immobilized and crosslinked agarose for potential application in the inhibition of infection and omental 
wrapping. Adv. Funct. Mater. 2014, 24, 1631–1643, doi:10.1002/adfm.201302242. 
161. Wu, F.; Xu, T.; Zhao, G.; Meng, S.; Wan, M.; Chi, B.; Mao, C.; Shen, J. Mesoporous Silica 
Nanoparticles-Encapsulated Agarose and Heparin as Anticoagulant and Resisting Bacterial Adhesion 
Coating for Biomedical Silicone. Langmuir 2017, 33, 5245–5252, doi:10.1021/acs.langmuir.7b00567. 
162. Shao, Q.; Jiang, S. Molecular understanding and design of zwitterionic materials. Adv. Mater. 2015, 27, 15–
26, doi:10.1002/adma.201404059. 
163. Zhang, X.; Wang, L.; Levänen, E. Superhydrophobic surfaces for the reduction of bacterial adhesion. RSC 
Adv. 2013, 3, 12003–12020, doi:10.1039/c3ra40497h. 
164. Yuan, Y.; Hays, M.P.; Hardwidge, P.R.; Kim, J. Surface characteristics influencing bacterial adhesion to 
polymeric substrates. RSC Adv. 2017, 7, 14254–14261, doi:10.1039/c7ra01571b. 
165. Falde, E.J.; Yohe, S.T.; Colson, Y.L.; Grinstaff, M.W. Superhydrophobic Materials for Biomedical 
Applications. Biomaterials 2016, 104, 87–103, doi:10.1016/j.biomaterials.2016.06.050. 
166. Izquierdo-Barba, I.; García-Martín, J.M.; Álvarez, R.; Palmero, A.; Esteban, J.; Pérez-Jorge, C.; Arcos, D.; 
Vallet-Regí, M. Nanocolumnar coatings with selective behavior towards osteoblast and Staphylococcus 
aureus proliferation. Acta Biomater. 2015, 15, 20–28, doi:10.1016/j.actbio.2014.12.023. 
167. Ma, M.; Hill, R.M. Superhydrophobic surfaces. Curr. Opin. Colloid Interface Sci. 2006, 11, 193–202, 
doi:10.1016/j.cocis.2006.06.002. 
168. Yan, Y.Y.; Gao, N.; Barthlott, W. Mimicking natural superhydrophobic surfaces and grasping the wetting 
process: A review on recent progress in preparing superhydrophobic surfaces. Adv. Colloid Interface Sci. 
2011, 169, 80–105, doi:10.1016/j.cis.2011.08.005. 
169. Feng, L.; Li, S.; Li, Y.; Li, H.; Zhang, L.; Zhai, J.; Song, Y.; Liu, B.; Jiang, L.; Zhu, D. Super-Hydrophobic 
Surfaces: From Natural to Artificial. Adv. Mater. 2002, 14, 1857–1860, doi:10.1002/adma.200290020. 
170. Crick, C.R.; Ismail, S.; Pratten, J.; Parkin, I.P. An investigation into bacterial attachment to an elastomeric 
superhydrophobic surface prepared via aerosol assisted deposition. Thin Solid Films 2011, 519, 3722–3727, 
doi:10.1016/j.tsf.2011.01.282. 
171. Yang, H.; You, W.; Shen, Q.; Wang, X.; Sheng, J.; Cheng, D.; Cao, X.; Wub, C. Preparation of lotus-leaf-like 
antibacterial film based on mesoporous silica microcapsule-supported Ag nanoparticles. RSC Adv. 2014, 
12, 2793–2796, doi:10.1039/c3ra45382k. 
172. Zimmerli, W.; Moser, C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS 
Immunol. Med. Microbiol. 2012, 65, 158–168, doi:10.1111/j.1574-695X.2012.00938.x. 
Pharmaceutics 2018, 10, x 30 of 30 
 
173. Fakhro, A.; Jalalabadi, F.; Brown, R.H.; Izaddoost, S.A. Treatment of Infected Cardiac Implantable 
Electronic Devices. Semin. Plast. Surg. 2016, 30, 60–65, doi:10.1055/s-0036-1580733. 
174. Wu, H.; Moser, C.; Wang, H.-Z.; Høiby, N.; Song, Z.-J. Strategies for combating bacterial biofilm infections. 
Int. J. Oral Sci. 2014, 7, 1–7, doi:10.1038/ijos.2014.65. 
175. Arita-Morioka, K.I.; Yamanaka, K.; Mizunoe, Y.; Ogura, T.; Sugimoto, A.S. Novel strategy for biofilm 
inhibition by using small molecules targeting molecular chaperone DnaK. Antimicrob. Agents Chemother. 
2015, 59, 633–641, doi:10.1128/AAC.04465-14. 
176. Gaidhani, S.; Singh, R.; Singh, D.; Patel, U.; Shevade, K.; Yeshvekar, R.; Ananda Chopade, B. Biofilm 
disruption activity of silver nanoparticles synthesized by Acinetobacter calcoaceticus PUCM 1005. Mater. 
Lett. 2013, 108, 324–327, doi:10.1016/j.matlet.2013.07.023. 
177. Lu, T.K.; Collins, J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. 
USA 2007, 104, 11197–11202, doi:10.1073/pnas.0704624104. 
178. Baker, P.; Hill, P.J.; Snarr, B.D.; Alnabelseya, N.; Pestrak, M.J.; Lee, M.J.; Jennings, L.K.; Tam, J.; Melnyk, 
R.A.; Parsek, M.R.; et al. Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt 
and prevent Pseudomonas aeruginosa biofilms. Sci. Adv. 2016, 2, doi:10.1126/sciadv.1501632. 
179. Rukavina, Z.; Vanić, Ž. Current trends in development of liposomes for targeting bacterial biofilms. 
Pharmaceutics 2016, 8, 18, doi:10.3390/pharmaceutics8020018. 
180. Robinson, A.M.; Creeth, J.E.; Jones, M.N. The use of immunoliposomes for specific delivery of 
antimicrobial agents to oral bacteria immobilized on polystyrene. J. Biomater. Sci. Polym. Ed. 2000, 11, 1381–
1393, doi:10.1163/156856200744408. 
181. Andreozzi, E.; Barbieri, F.; Ottaviani, M.F.; Giorgi, L.; Bruscolini, F.; Manti, A.; Battistelli, M.; Sabatini, L.; 
Pianetti, A. Dendrimers and Polyamino-Phenolic Ligands: Activity of New Molecules Against Legionella 
pneumophila Biofilms. Front. Microbiol. 2016, 7, 289, doi:10.3389/fmicb.2016.00289. 
182. Hou, S.; Zhou, C.; Liu, Z.; Young, A.W.; Shi, Z.; Ren, D.; Kallenbach, N.R. Antimicrobial dendrimer active 
against Escherichia coli biofilms. Bioorg. Med. Chem. Lett. 2009, 19, 5478–5481, 
doi:10.1016/j.bmcl.2009.07.077. 
183. Vyas, S.; Sihorkar, V.; Dubey, P.K. Preparation, characterization and in vitro antimicrobial activity of 
metronidazole bearing lectinized liposomes for intra-periodontal pocket delivery. Pharmazie 2001, 56, 554–
560. 
184. Xu, C.; He, Y.; Li, Z.; Ahmad Nor, Y.; Ye, Q. Nanoengineered hollow mesoporous silica nanoparticles for 
the delivery of antimicrobial proteins into biofilms. J. Mater. Chem. B 2018, 6, 1899–1902, 
doi:10.1039/C7TB03201C. 
185. Pedraza, D.; Díez, J.; Izquierdo-Barba, I.; Colilla, M.; Vallet-Regí, M. Amine-Functionalized Mesoporous 
Silica Nanoparticles: A New Nanoantibiotic for Bone Infection Treatment. Biomed. Glas. 2018, 4, 1–12, 
doi:10.1515/bglass-2018-0001. 
186. Stanton, M.M.; Park, B.W.; Vilela, D.; Bente, K.; Faivre, D.; Sitti, M.; Sánchez, S. Magnetotactic Bacteria 
Powered Biohybrids Target E. coli Biofilms. ACS Nano 2017, 11, 9968–9978, doi:10.1021/acsnano.7b04128. 
© 2018 by the authors. Submitted for possible open access publication under the terms 
and conditions of the Creative Commons Attribution (CC BY) license 
(http://creativecommons.org/licenses/by/4.0/). 
 
